Method for membrane gas transfer in high-density bioreactor culture

Non-porous hollow fiber membrane modules in bioreactors facilitate bubble-free gas exchange, addressing bubble-related cell death and foam formation, enabling high-density cell cultures with sustained oxygen levels and improved productivity.

KR103044365B1Active Publication Date: 2026-11-06BOEHRINGER INGELHEIM INT GMBH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
KR1020217014110
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Priority Date
2018-10-10
Filing Date
2019-10-08
Publication Date
2026-11-06
Estimated Expiration
2039-10-08

AI Technical Summary

Technical Problem

Existing bioreactor systems face challenges in achieving high cell densities due to bubble-related cell death and foam formation during gas exchange, necessitating the use of antifoaming agents that can be toxic, and existing membrane designs limit gas transfer efficiency at high densities.

Method used

The use of non-porous hollow fiber membrane modules for gas transfer in bioreactors, which allow for bubble-free gas exchange, maintaining dissolved oxygen levels and preventing foam formation, thereby supporting high cell densities without cell damage.

Benefits of technology

The solution enables sustained dissolved oxygen levels and high cell viability, allowing for high-density cell cultures with increased productivity and reduced reliance on antifoaming agents.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112021054058717-PCT00012_ABST
    Figure 112021054058717-PCT00012_ABST
Patent Text Reader

Abstract

The present invention provides an improved bioprocess system and bioprocess method for cell culture using an improved bioreactor for the production of monoclonal antibodies or bispecific antibodies, e.g., a fed-batch or perfusion bioreactor cell culture system, said system and method which are modified to include one or more membrane gas delivery modules instead of a sparger- or microsparger-based aeration system, thereby better controlling the levels of important gases, e.g., dissolved O2 levels and CO2 levels, in bioreactor cell culture, even at high cell densities, without the cells undergoing bubble-induced cell death.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present invention generally relates to the field of bioprocessing, for example, the production of monoclonal antibodies, bispecific antibodies, or other proteins of interest in bioreactor cell cultures. The present invention also relates to a method and apparatus for improving bioreactor cell culture conditions to achieve high-density cell culture. Furthermore, the present invention relates to a method and apparatus for increasing cell culture density and product potency by achieving improved gas exchange conditions in bioreactor cell cultures. Background Technology

[0002] Recent technological developments have enabled cell cultures to achieve very high cell densities, which leads to high productivity of biologics, such as monoclonal or bispecific antibodies.[1] However, controlling dissolved oxygen (DO) in these bioprocesses remains a challenging task, as it requires the delivery of high levels of oxygen and carbon dioxide to support high-density cultures. To achieve high levels of gas delivery, methods such as microsparging, which releases micron-sized bubbles into the reactor, are used.[2] However, the use of microsparging increases the risk of bubble-burst-related cell death and foam-out in the bioreactor, which can lead to premature run termination and product loss.[3,4] Furthermore, the addition of antifoaming agents and shear protectants to prevent foam-out and bubble-burst-related cell death must be applied at levels that, in extreme cases, can be toxic to the cells.[5]

[0003] To eliminate challenges associated with microsparging, bubble-free aeration methods using porous and non-porous membranes have been investigated for cell culture applications. For example, polymeric porous membranes with micron-sized pores have been described as bubble-free aeration methods, where the pressure balance between the culture and the gas allows bubble-free transfer to occur at the gas-liquid interface through the membrane pores.[6 to 8] In another example, the use of hydrophobic membranes (which prevent pore wetting issues) has demonstrated improved gas transfer compared to hydrophilic membranes, as the liquid trapped within the pores creates an additional barrier to gas transfer to the culture.[9] Non-porous silicone polymer-based membranes (e.g., polydimethylsiloxane, PDMS) have also been used for bubble-free gas transfer, where gas molecules diffuse through the dense polymer and are transferred to the culture at the membrane-culture contact surface.[10 to 12]

[0004] Although porous and non-porous membranes have been applied to cell culture, only low densities (i.e., <20 e6 cells / mL) have been achieved due to limitations in membrane design and challenges related to membrane operation.

[13] For example, in the case of porous membranes, cell culture can be compromised because micron-sized bubbles can form when gas pressure and culture pressure are improperly balanced. Conversely, in the case of non-porous membranes, the slow mass transfer of passing gas molecules hinders sufficient gas exchange to support high-density culture.

[0005] To overcome the many problems associated with sparging-based gas exchange processes in high-density cell culture, alternative methods and materials for bubble-free gas exchange are required.

[0006] Generally, the present invention relates to a bioreactor and a bioprocess method using the bioreactor. The present invention partially replaces a sparger (e.g., used for oxygenation and / or introduction of gas into the cell culture) of a high-density cell culture bioreactor with one or more hollow fiber membrane modules, thereby allowing for high cell densities (e.g., at least 120 x 10⁻⁶) without significantly affecting the viability of the culture during operation. 6 This concerns the surprising discovery that sustained dissolved oxygen levels (e.g., 60% DO) can be achieved in cells / mL. As a result, the cells used in the biological process remain viable throughout the process, thereby increasing the productivity of the bioreactor.

[0007] In one aspect, the present invention provides a method for culturing cells in a bioreactor, comprising the step of providing mass transfer of a gas to / from the bioreactor without generating bubbles inside the bioreactor. In a specific embodiment, the bioreactor of the present invention is a perfusion bioreactor. The bioreactor of the present invention may also be a fed-batch bioreactor.

[0008] In certain embodiments, mass transfer of gas to / from a bioreactor is provided by a gas transfer module. In various embodiments, the gas transfer module comprises a non-porous membrane, said non-porous membrane may be, for example, a polymer, a metal, or a ceramic. The polymer may include a silicone gum homopolymer, polydimethylsiloxane (PDMS), or a silicone-polycarbonate copolymer. In various embodiments, the non-porous membrane comprises a plurality of hollow fibers.

[0009] In various embodiments, the gas delivery module of the present invention comprises a first flow path through hollow fibers for passing one or more gases and a second flow path around hollow fibers for flowing cell culture media and / or cells.

[0010] In another embodiment, the gas transfer module of the present invention is located outside the bioreactor.

[0011] In a specific embodiment, a plurality of hollow fibers of the present invention provide a flow path through which a culture medium and cells travel through spaces separating the hollow fibers. The spaces of the present invention may be homogeneous or heterogeneous. The spaces of the present invention may be of a size sufficient for cells to pass through without causing shear force on the cells. In a specific embodiment, the spaces of the present invention include a distance of about 15 to about 2,000 µm. In other specific embodiments, the spaces of the present invention comprise distances of 15 to 30 µm, 20 to 40 µm, 30 to 60 µm, 40 to 80 µm, 60 to 120 µm, 80 to 160 µm, 100 to 200 µm, 150 to 300 µm, 200 to 400 µm, 200 to 500 µm, 200 to 600 µm, 200 to 700 µm, 200 to 800 µm, 200 to 900 µm, 200 to 1,000 µm, or 500 to 2,000 µm, or a combination of these distances.

[0012] In various embodiments, the flow of the cell culture medium and / or cells comprises tangential flow, axial flow, or a combination of these flows. The flow of the cell culture medium and / or cells may be at a speed sufficient to maintain culture homogeneity without causing shear force to the cells.

[0013] In various embodiments, the gas of the present invention may be carbon dioxide, oxygen or nitrogen or other gases or even air.

[0014] In various embodiments, the cell density of the bioreactor of the present invention is approximately 20x10 6 cell / ml, approx. 30x10 6 cell / ml, approx. 40x10 6 cell / ml, approx. 50x10 6 cell / ml, approx. 60x10 6cell / ml, approx. 70x10 6 cell / ml, approx. 80x10 6 cell / ml, approx. 90x10 6 cell / ml, approx. 100x10 6 cell / ml, approx. 110x10 6 cell / ml, approx. 120x10 6 cell / ml, approx. 130x10 6 cell / ml, approx. 140x10 6 cell / ml, approx. 150x10 6 cell / ml, approx. 160x10 6 cell / ml, approx. 170x10 6 cell / ml, approx. 180x10 6 cell / ml, approx. 190x10 6 cell / ml, approx. 200x10 6 cell / ml, approx. 210x10 6 cell / ml, approx. 220x10 6 cell / ml, approx. 230x10 6 cell / ml, approx. 240x10 6 cell / ml or approximately 250x10 6 It is cell / ml.

[0015] In various embodiments, the method of the present invention prevents foam formation and / or does not require an antifoaming agent during cell culture.

[0016] In another embodiment, the bioreactor of the present invention does not include headspace or does not substantially include headspace.

[0017] In various embodiments, the bioreactor of the present invention comprises two or more gas transfer modules. The two or more gas transfer modules of the present invention can provide mass transfer of various gases, including oxygen, carbon dioxide, or nitrogen gas, and even air.

[0018] In another aspect, the present invention provides a bioreactor system for high-density cell culture, comprising a bioreactor vessel for growing cells in a cell culture medium and a liquid flow path that fluidly communicates with said bioreactor vessel, wherein the liquid flow path forms a circuit for translocating the cell culture medium through a first membrane gas transfer module and a second membrane gas transfer module outside said bioreactor vessel.

[0019] In various embodiments, the first membrane gas delivery module of the present invention is for adding oxygen to the cell culture medium of the present invention.

[0020] In another embodiment, the second membrane gas delivery module of the present invention is for stripping carbon dioxide from the cell culture medium of the present invention.

[0021] In another embodiment, the first membrane gas delivery module of the present invention includes an oxygen flow path and a cell culture medium flow path, and said gas flow path and cell culture flow path are separated by a gas permeable membrane.

[0022] In another embodiment, the first membrane gas delivery module of the present invention comprises an air / carbon dioxide flow path and a cell culture medium flow path, and said air / carbon dioxide flow path and cell culture flow path are separated by a gas-permeable membrane.

[0023] The liquid flow path of the bioreactor described herein may further include one or more additional elements, said elements may include a cell harvesting filter, a perfusion pump, an oxygen source, an air / carbon dioxide source, an oxygen sensor and / or a pH sensor.

[0024] In the various embodiments of the bioreactors described herein, the cell density of the high-density cell culture is approximately 20 x 10 6cell / ml, approx. 30x10 6 cell / ml, approx. 40x10 6 cell / ml, approx. 50x10 6 cell / ml, approx. 60x10 6 cell / ml, approx. 70x10 6 cell / ml, approx. 80x10 6 cell / ml, approx. 90x10 6 cell / ml, approx. 100x10 6 cell / ml, approx. 110x10 6 cell / ml, approx. 120x10 6 cell / ml, approx. 130x10 6 cell / ml, approx. 140x10 6 cell / ml, approx. 150x10 6 cell / ml, approx. 160x10 6 cell / ml, approx. 170x10 6 cell / ml, approx. 180x10 6 cell / ml, approx. 190x10 6 cell / ml, approx. 200x10 6 cell / ml, approx. 210x10 6 cell / ml, approx. 220x10 6 cell / ml, approx. 230x10 6 cell / ml, approx. 240x10 6 cell / ml or approximately 250x10 6 It is cell / ml.

[0025] In various embodiments, the first membrane gas delivery module and the second membrane gas delivery module of the present invention add / add or remove gas to / from the cell culture medium of the present invention without forming bubbles.

[0026] Details of one or more embodiments of this specification are described in the following description. Other characteristic features or advantages of this specification will become apparent from the drawings and the detailed description of various embodiments below, as well as from the appended claims. Brief explanation of the drawing

[0027] The following drawings are incorporated to form part of the invention and to further demonstrate specific aspects of the invention, and may be better understood in conjunction with the detailed description of specific embodiments presented herein with reference to one or more of these drawings. FIG. 1a provides a schematic diagram of a bioreactor (100) known in the art comprising a sparger (or microsparger) (106) for gas delivery to a cell culture (103) and a source of oxygen / air / carbon dioxide or other gas (110). Bioreactors (100) of the latest technology form or generate bubbles or microbubbles (107) during the gas delivery process, which are harmful to the cultured cells and can form foam, which may result in low cell density and / or cell culture product yield. FIG. 1b illustrates a schematic diagram of an embodiment of the bioreactor disclosed herein. In the embodiment, the improved bioreactor (300) comprises one or more externally located membrane gas transfer modules (309), wherein the modules are supplied with cell culture along a series of flow paths (314) from / to the bioreactor by a pump (312). The first membrane gas transfer module (309b) has a gas inlet (310b) and a gas outlet (311b). The second membrane gas transfer module (309a) also has a gas inlet (310a) and a gas outlet (311a). A pump (312) moves the cell culture from the bioreactor (300) along a flow path (314) (i.e., a recirculation loop) through a first membrane gas transfer module (309b) and then through a second membrane gas transfer module (309a), allowing the cell culture to interact with the gas and flow through the membrane modules, with the gas entering at the gas inlet and exiting at the outlet port. The gas passes through the gas-permeable membrane of the module and interacts with the cell culture, and the module separates the gas flow zone from the cell culture flow path. The module enables the addition and / or addition of a specific gas (e.g., oxygen) or the removal of another gas (e.g., CO2) from the bioreactor cell culture without the generation of bubbles. The cell culture processed by the module along the flow path (314) is returned to the bioreactor (300). The precise configuration illustrated in FIG. 1b is not intended to limit other available configurations considered in the present invention. A computer controller may be included to blend O2, CO2, N2, air, or other gas flows to the membrane to maintain dissolved O2 and CO2 at desirable concentrations in the bioreactor. FIG. 1c illustrates a typical 2-liter (2L) working volume glass stirred tank bioreactor system (400) with a TFF recirculation loop (409 and 411) comprising a pump (415), a filter (410), and a bubble-free membrane gas delivery module (412) that replaces a microsparger for high-density culture. Computer controllers (405 and 407) regulate the O2 gas flow (401) to the membrane (412) to maintain dissolved O2 in the solution. The carbon dioxide flow (402) and air flow (403) can be supplied directly to the growth vessel (408). A pH sensor (404) communicates with the CO2 flow, and the CO2 flow regulates the pH level of the cell culture. During operation, the cell culture is removed by flow 1 (409) via the perfusion pump (415), supplied through the filter (410) (TFF module), and optionally harvested. A portion of the flow may pass through the filter (410) and be returned to the cell culture vessel via flow 2 (411). A second portion of the flow may pass through the filter (410) and enter the membrane gas delivery module (412), which may be oxygenated by interaction with the oxygen flow (401) and optionally blended with air (403). Carbon dioxide may be stripped through the discharge section (414). Carbon dioxide may also be released through the headspace discharge section (413). FIG. 1d illustrates a 2-liter (2L) bubble-free high-density bioreactor system (500) comprising a TFF recirculation loop (flow paths 509 and 511), a TFF filter (510), a pump (515), and a series of membrane gas transfer modules (512a and 512b) for adding and removing gas from a high-density cell culture without the addition of bubbles. The first module (512a) functions to oxygenate the cell culture medium to maintain a sustained dissolved oxygen ("DO") content or a desired concentration. The first module (512a) is supplied by a flow of oxygen (503). The oxygen level of the cell culture is measured by a dissolved oxygen sensor (505). The second membrane gas transfer module (512b) functions to strip carbon dioxide from the cell culture. The second membrane gas transfer module (512b) is supplied by a flow of air (501) (containing nitrogen gas necessary for carbon dioxide stripping) and a flow of carbon dioxide (502). Subsequently, the flow levels of 501 and 502 are controlled by a pH sensor (504) and a computer (506). FIG. 1e illustrates a generalized schematic diagram of a membrane gas delivery module (600) that may be used in connection with the improved bioreactor of the present invention. In a general but non-limiting configuration, the membrane module of the present invention may comprise a hollow fiber bundle (601) of gas-permeable hollow fiber tubes (609), said tubes secured together by a potting or seal (603) (not shown) and placed inside a housing or shell (605) (not shown) and fitted with an inlet cap (604) at each end to introduce a flow of one or more gases through the interior of each hollow fiber. The housing may also comprise one or more inlet / outlet ports (605 and 608) for a flow path of cell culture, said path entering into one port, flowing through the housing in the space surrounding the hollow fiber, and then exiting out of the outlet port. The housing may also include one or more inlet / outlet ports (606 and 607) for the flow of one or more gases through the inner lumen of each gas-permeable hollow fiber tube. In practice, the flow path of the cell culture is pumped into the inlet (605) on the housing, flows through the housing through the outer space around each hollow fiber of the hollow fiber bundle, and is discharged through the outlet port (608). At the same time, inside the housing, the cell culture comes into contact with the gas-permeable membrane of the hollow fiber bundle, said membrane carries the flow of one or more gases in the lumen space. In use, a “supply” mixture of gases may enter through the inlet port and flow into the interior of the hollow fiber (609). Gas is delivered from the interior of the hollow fiber through the gas-permeable membrane wall (610) into the cell culture flow path (which is outside the hollow fiber). Gas passing through the membrane is “permeable,” and gas remaining inside the hollow fiber is “retained.” FIG. 2 illustrates an embodiment of a membrane gas delivery module (800) that can be used in connection with the improved bioreactor described herein. The module of the present invention includes a "shell side in" inlet (801) for receiving cell culture medium, which extends across the entire housing or shell in the space surrounding each of the hollow fibers of the hollow fiber bundle. The culture medium eventually exits the housing through a "shell side out" outlet port (802). In the above example, there are two outlet ports; however, any number of outlet ports may be used. The module of the present invention also includes one or more "tube (lumen) side in" inlet ports (804) for receiving one or more gases or gas mixtures, said ports enter the lumen or internal space of each of the hollow fibers of the hollow fiber bundle. The gas then exits through one or more "tube (lumen) side out" outlet ports (803) along the length of the hollow fiber. This configuration establishes both a "gas flow zone" within the internal space of the hollow fiber lumen and a "medium or cell culture flow zone," which is a space outside the hollow fiber but confined within the shell or house. Gas in the gas flow zone can pass through the membrane and be transferred into the medium flow zone. Alternatively, dissolved gases (e.g., CO2) can pass through the hollow fiber membrane into the gas flow zone and exit the module in an "ejected" state through the gas outlet port. Figures 3a, 3b, and 3c illustrate various configurations of the gas flow path (arrows marked "*") and cell culture medium flow path (arrows marked "**") in a typical membrane gas transfer module. Ports marked "x" are blocked. Gas transfer efficiency is highest in the configuration of Figure 3c compared to the configurations of Figures 3a and 3b given the same flow rate. The table shown in Figure 3d indicates gas transfer with a surface area of ​​2,500 cm² 2Examples of measured kLa (liquid mass transfer coefficients) for oxygen transfer through a membrane gas transfer module are provided. Figures 3a and 3c, which are limitations on the flow path, hinder the ability to achieve flow rates exceeding 0.5 LPM (liters per minute). Different membrane sizes can be used for different kLa to support larger and smaller bioreactors. Figures 4a through 4c illustrate the viable cell density (VCD), viability, and LDH of a dedicated CHO cell line (CHO1) cultured in steady to abnormal operation by membrane gas exchange replacing a microsparger, for example, using the bioreactor system of Figures 1b, 1c, or 1d. Figure 4a illustrates that a steady-state VCD of 40 e6 cells / mL was achieved in perfusion culture using a sparger. After 4 days of steady-state operation, the microsparger in one of the reactors was turned off, and O2 was added through the membrane to maintain the DO (dissolved oxygen) required at the set point (*), and the system was operated in steady state for 3 days. After steady-state operation, cell release was reduced (**), and a density of 120 e6 cells was achieved by controlling the DO using O2 supplied through the membrane. Figure 4b illustrates that the viability (%) using membrane and conventional sparging is similar during the culture process. Figure 4c shows that the LDH (lactate dehydrogenase activity assay) of a bioreactor operated by membrane gas exchange matches the LDH of a bioreactor operated by conventional sparging. The increase in LDH for membrane culture after 13 days can be attributed to the increased cell density. Figures 5a through 5c illustrate DO (dissolved oxygen) levels during culture with membrane gas exchange during steady-state and unsteady-state operation using, for example, the bioreactor system of Figures 1b, 1c, or 1d. Figure 5a illustrates the baseline DO profile established during ramp-up to steady-state density. Microsparging was initiated on days 1 to 2 (*) and stabilized when a density of 40 e6 cell / mL was achieved on days 2 to 3. Figure 5b illustrates that the O2 line was switched to the membrane on day 7 (*). Fluctuations were controlled by adjusting the gain and integral (* to **), and sparging through a perforated hole sparger with a mixture of air (0.25 LPM) and O2 (0.25 LPM) rather than 0.5 LPM O2 further stabilized DO fluctuations because the membrane provides a very large amount of oxygen for culture (**). Figure 5c shows that cell release decreased on day 11 and density increased to 120 e6 cell / mL. Fluctuations in DO may have occurred due to wetting of the fiber and gas outlet vent filter, which may result in the blockage and loss of gas delivery during operation. Figures 6a through 6c illustrate the viable cell density (VCD), viability, and lactate dehydrogenase activity (LDH) of CHO1 cells cultured during ramp-up to high cell density using, for example, the bioreactor systems of Figures 1b, 1c, or 1d. Figure 6a shows that a density of ~130 e6 cells / mL is reached during ramp-up to high cell density with traditional sparging, whereas a density of ~100 x 106 cells / mL is reached with membrane gas exchange. Shearing from the membrane can affect culture viability during ramp-up to high density. Figure 6b shows that cells have similar viability (>85%) during the culture process for both membrane and sparger aeration. Figure 6c shows that LDH is similar in both membrane gas exchange and conventional sparging. Higher LDH is expected for cultures using conventional sparging due to higher cell density, indicating that membrane exchangers can cause shear and damage to cells during operation. Figures 7a through 7c illustrate the control of DO during ramp-up to high cell densities using the bioreactor systems of Figures 1b, 1c, or 1d. Figure 7a illustrates that DO was initially controlled by sparging through a perforated hole sparger. As density increased, additional O2 was transferred across the membrane to maintain DO at 60%(*). Due to the shutdown of the MFC, significant fluctuations and problems occurred in controlling DO during the membrane startup phase. When control was restored to the MFC, DO fluctuated around the setpoint and eventually reached normal operation at a cell density of approximately 80e6 cell / mL on days 6 to 7. Figure 7b illustrates that at peak density, control of DO across the membrane remained stable, with only a few fluctuations occurring during the transient shutdown of the MFC. Figure 7c illustrates daily pO2 readings monitored offline throughout the entire culture period, showing levels of dissolved oxygen similar to those in cultures controlled by sparging or membrane gas exchange. Figures 8a through 8c illustrate the viable cell density (VCD), viability, and lactate dehydrogenase activity (LDH) of CHO2 cells cultured in a membrane-operated bioreactor for bubble-free aeration, for example, using the bioreactor systems of Figures 1b, 1c, or 1d. Figure 8a shows that a viable cell density of 25 to 30 e6 cells / mL was achieved in the culture over several weeks. The membrane culture took an additional day to reach steady-state operating density, indicating that the membrane may have a slight effect on culture viability. Figure 8b illustrates that the viability of the membrane culture was slightly lower than that of conventional sparging, further demonstrating the effect of the membrane on the cells. Figure 8c shows that the LDH of the membrane culture was higher than that of the bubble-sparged bioreactor, indicating that cell shearing and lysis may occur due to the densely packed fibers in current membrane unit designs. Figures 9a and 9b illustrate the control of DO (dissolved oxygen) by bubble-free gas exchange through silicon-based membranes using, for example, the bioreactor systems of Figures 1b, 1c, or 1d. Figure 9a shows a controlled DO of approximately 60% during culture supporting CHO2 densities of 25 to 30 e6 cells / mL. On day 7, recirculation was increased to support oxygen requirements at high cell densities (*). On day 9, control was switched to manual to better control DO fluctuations (**). Figure 9b shows daily pO2 and pCO2 readings monitored offline throughout the entire culture period, demonstrating similar levels of dissolved oxygen in cultures controlled by sparging or membrane gas exchange. The increase in pCO2 on day 6 is likely due to 100% pure O2 flow across both membranes. To resolve the high pCO2, air was mixed with O2 through the first sparger, and the pCO2 was returned to a level similar to that of the sparger culture. Figure 10 illustrates an initial test of O2 transfer using the bioreactor systems of Figures 1b, 1c, or 1d, which consist of a 100L volume filled with 65L of water, compared to the state-of-the-art bioreactor of Figure 1a. Faster gas transfer was observed in the membrane-based bioreactor compared to the built-in sparger system. FIG. 11 shows that the pump speed is higher for the flow path shown in FIG. 3c to achieve a flow rate run similar to that shown in FIG. 3b, which indicates a limitation in flow path C (top graph). Due to this limitation, a higher pressure is observed in flow path C (bottom graph). Specific details for implementing the invention

[0028] Oxygen supply is a key element of cellular aerobic metabolic processes because it acts as the primary electron acceptor during energy synthesis. Ensuring an efficient supply of dissolved oxygen is the greatest challenge faced by the operation of cell culture bioreactors for general high-density cell culture biological processes, particularly in commercial production scenarios, such as the clinical production of monoclonal or bispecific antibodies. In addition to supplying oxygen to the cells, the concentration of dissolved carbon dioxide also serves as a controlled variable.

[0029] There are two common aeration methods in bioreactors: headspace aeration and direct gas injection through an aeration ring. These devices are more commonly known as "spargers" or "microspargers" depending on the size of the gas opening pores. Spargers, including perforated holes or open pipe spargers, generally have a gas outlet opening of, for example, 0.8 mm, whereas microspargers, typically made of sintered plastic or metal, have pore sizes of, for example, 15 to 45 µm. Both types have specific advantages and disadvantages. Spargers generate larger bubbles, which require a higher gas throughput rate to achieve the same "oxygen delivery rate." However, spargers can cause bubble-induced cytotoxicity by introducing shear forces to the cells as the bubbles pass through the cell culture. However, one advantage of spargers is that, due to the larger size of the bubbles, they are suitable for stripping or sweeping out CO2. Microspargers were primarily developed to improve gas delivery to cell cultures by reducing the size of bubbles introduced into the culture. However, microspargers tend to generate foam as a result of microbubbles interacting with proteins within the cell culture, which can lead to premature run termination and loss of products. Similar to spargers, microbubbles generated by microspargers also induce shear forces on cultured cells. In particular, these shear forces can cause membrane damage and cell death due to bubble ejection near the cells.

[0030] The present invention relates, in part, to the surprising discovery that by replacing a sparger or microsparger with one or more hollow fiber membrane modules in the context of a high-density cell culture bioreactor, sustained levels of dissolved oxygen at high cell densities can be achieved without severely affecting culture vitality during operation. Accordingly, the present invention relates to an improved bioprocess system and bioprocess method for cell culture using an improved bioreactor, e.g., a fed-batch or perfusion bioreactor cell culture system for the production of monoclonal or bispecific antibodies, wherein, instead of a sparger- or microsparger-based aeration system, one or more membrane gas delivery modules are included, thereby modifying the levels of critical gases in the bioreactor cell culture—e.g., dissolved O2 and CO2 levels—to be better controlled, even at high cell densities, without the cells undergoing shear and bubble-induced cell death. Non-limiting aspects and aspects are provided in the embodiments, drawings, and the following description.

[0031] definition

[0032] Unless otherwise defined, all technical and scientific terms used herein have the meaning generally understood by a person skilled in the art to which the present invention pertains. The following references provide general definitions of many terms used in the present invention to a person skilled in the art to which the present invention pertains: Singleton et al., Dictionary of Microbiology and Molecular Biology (2d ed. 1994); The Cambridge Dictionary of Science and Technology (Walker ed., 1988); Hale & Marham, The Harper Collins Dictionary of Biology (1991); and Lackie et al., The Dictionary of Cell & Molecular Biology (3d ed. 1999); and Cellular and Molecular Immunology, Eds. Abbas, Lichtman and Pober, 2nd Edition, WB Saunders Company. For the purposes of the present invention, the following terms are further defined.

[0033] The singular forms "a," "an," and "the" used in this application and the claims include singular and plural subjects unless the context otherwise indicates. Thus, for example, a reference to "preparation" includes a single preparation and multiple such preparations.

[0034] Note that in this application and particularly in the claims and / or paragraphs, terms such as “comprise,” “comprised,” “comprising,” etc. may have meanings derived from U.S. patent law, e.g., “include,” “included,” “including,” etc.; and terms such as “essentially constituted” and “essentially constituted” have meanings defined in U.S. patent law, e.g., allowing for elements not explicitly mentioned but excluding elements found in the prior art or affecting the fundamental or novel characteristics of the invention.

[0035] The term "acquisition," as in "acquisition of apo-related protein," is intended to include purchasing, synthesizing, or otherwise acquiring apo-related proteins (or the indicated substances or materials).

[0036] "Isolated cell" refers to a cell naturally associated with a cell isolated from another component and / or a cell isolated from a tissue or mammal.

[0037] As used herein, "sample" refers to a composition comprising biological material, for example (but not limited to) a bioreactor cell culture sample.

[0038] "Cell culture" or "culture" refers to the growth and proliferation of cells outside of a multicellular organism or tissue. Culture conditions suitable for mammalian cells are known in the art. For example, see the literature [Animal cell culture: A Practical Approach, D. Rickwood, ed., Oxford University Press, New York (1992)]. Mammalian cells may be cultured in a suspension or attached to a solid substrate. Fluidized bed bioreactors with or without microcarriers, hollow fiber bioreactors, roller bottles, shaking flasks, or stirred tank bioreactors may be used. In one embodiment, a 500 to 2,000 L bioreactor is used. In a preferred embodiment, a 1,000 L to 2,000 L bioreactor is used. For the purposes of the present invention, the cell culture medium is a medium suitable for the growth of animal cells, such as mammalian cells, in in vitro cell culture. Formulations of cell culture media are widely known in the art. Generally, cell culture media consist of buffers, salts, carbohydrates, amino acids, vitamins, and trace essential elements. "Serum-free" applies to cell culture media that do not contain animal serum, such as fetal bovine serum. Various tissue culture media, including limited culture media, are commercially available, and, for example, any one or a combination of the following cell culture media may be used: among others, RPMI-1640 medium, RPMI-1641 medium, Dulbecco modified Eagle medium (DMEM), Minimum Essentials medium Eagle, F-12K medium, Ham F12 medium, Iscove modified Dulbecco medium, McCoy 5A medium, Leibovitz L-15 medium, serum-free media, for example, EX-CELL™ 300 series (JRH Biosciences, Lenexa, Kansas). Serum-free versions of these culture media are also available.Cell culture media may be supplemented with additional or increased concentrations of components, such as amino acids, salts, sugars, vitamins, hormones, growth factors, buffers, antibiotics, lipids, trace elements, etc., depending on the requirements of the cells being cultured and / or the desired cell culture parameters.

[0039] As used herein, the term "low-density cell culture" refers to a cell concentration of 20 x 10⁶ per 1 ml. 6 It indicates a cell culture of less than 1 cell.

[0040] As used herein, the term "high-density cell culture" refers to a cell concentration of 20 x 10 per 1 ml. 6 It indicates a cell culture with more than 10 cells. High-density cell culture has a concentration of approximately 25 x 10⁶ per 1 ml. 6 cell, approximately 35 x 10⁶ per 1 ml 6 cell, approximately 45 x 10⁶ per 1 ml 6 cell, approximately 55 x 10⁶ per 1 ml 6 cell, approximately 65 x 10⁶ per 1 ml 6 cell, approximately 75 x 10⁶ per 1 ml 6 cell, approximately 85 x 10⁶ per 1 ml 6 cell, approximately 95 x 10⁶ per 1 ml 6 cell, approximately 100x10 per 1ml 6 cell, approximately 110 x 10⁶ per 1 ml 6 cell, approximately 120 x 10⁶ per 1 ml 6 cell, approximately 130 x 10⁶ per 1 ml 6 cell, approximately 140 x 10⁶ per 1 ml 6 cell, approximately 150 x 10⁶ per 1 ml 6 cell, approximately 160 x 10⁶ per 1 ml 6 cell, approximately 170 x 10⁶ per 1 ml 6 cell, approximately 180 x 10⁶ per 1 ml 6 cell, approximately 190 x 10⁶ per 1 ml 6 cell, approximately 200x10 per 1ml 6 cell, approximately 210 x 10⁶ per 1 ml 6cell, approximately 220 x 10⁶ per 1 ml 6 cell, approximately 230 x 10⁶ per 1 ml 6 cell, approximately 240 x 10⁶ per 1 ml 6 cell, approximately 250 x 10⁶ per 1 ml 6 cell, approximately 260 x 10⁶ per 1 ml 6 cell, approximately 270 x 10⁶ per 1 ml 6 cell, approximately 280 x 10⁶ per 1 ml 6 cell, approximately 290 x 10⁶ per 1 ml 6 cell and approximately 300x10 per 1ml 6 It includes cell culture.

[0041] bioreactor

[0042] The improved bioreactors described herein may be derived from known bioreactor systems, particularly bioreactors comprising sparger or microsparger systems for performing culture aeration. Bioreactors are generally used in biological processes. As used herein, the term "bioreactor" may refer to any fabricated or constructed device or system that supports a biologically active environment. In one case, a bioreactor is a vessel in which a chemical process involving an organism or a biochemically active substance derived from such organism is carried out. This process may be aerobic or anaerobic. Such bioreactors are generally cylindrical in size ranging from liters to cubic meters and are often made of stainless steel or other materials. A bioreactor may also refer to a device or system for growing cells or tissues, often in the context of cell culture, with the aim of producing a desired biologically produced product, for example, a monoclonal antibody or a bispecific antibody. "Biological process" refers to an aerobic and anaerobic process involving cells in a growth medium, said cells producing one or more useful biological products or substances, such as monoclonal antibodies, bispecific antibodies, and enzymes (naturally or through genetic engineering). Examples of biological processes include yeast fermentation, bacterial fermentation, mammalian cell culture, bacterial culture, and the production of products using cells, such as mammalian cells like CHO cells for expressing proteins, such as therapeutic proteins or enzymes.

[0043] A bioreactor generally comprises a vessel where the biological process is performed, as well as sensors and process controls that enable the monitoring and control of process parameters. Bioreactors also typically include a shaker, such as a Rushton or marine impeller, to mix the vessel contents during the biological process. Generally, it is important to carefully control process parameters during the biological process, such as gas flow rate, temperature, pH, dissolved oxygen levels, and shaking rates and conditions. Dissolved oxygen levels are a measure of oxygen transfer from the gaseous phase to the liquid phase; they are critical in many biological processes and can be difficult to achieve. While oxygen transfer is generally aided by shaking, shaking rates are often limited by power consumption and, in some cases, the risk of damage to microorganisms. In some cases, for example, with mammalian cells, microorganisms are fragile and may be sensitive to heat, shear, and / or other process conditions.

[0044] The bioreactors used herein may be permanent (e.g., stainless steel or glass bioreactors) or disposable (e.g., plastic flasks or bags). Examples of reactors suitable for use in the present invention include, but are not limited to, stirred tank vessels, airlift vessels, and disposable bags that can be mixed by shaking, shaking, or stirring. Preferably, disposable (biological)reactors are used because they are advantageous due to the relatively low investment cost, excellent operational flexibility, short processing time, and ease of configuration for the process. Disposable (biological)reactors are commercially available.

[0045] The bioreactors that can be used in the present invention may be selected depending on the type of biological process of interest. For example, mammalian cell biological processes generally occur in three main forms: batch culture, fed-batch culture, and perfusion culture. Batch culture is a discontinuous method in which cells are grown in a fixed volume of culture medium for a short period of time and then completely harvested. In cultures grown using the batch method, cell density increases until a maximum cell density is reached, after which viable cell density decreases as medium components are consumed and levels of metabolic byproducts (e.g., lactate and ammonia) accumulate. Harvesting generally occurs when the maximum cell density is achieved (e.g., typically 5 to 10 x 10⁶ depending on the medium formulation, cell line, etc.). 6 cell / mL). Batch biological processes are the simplest culture methods, but viable cell density is limited by nutrient availability; once cells reach maximum density, the culture declines and production decreases. Because the culture declines rapidly due to the accumulation of waste products and nutrient depletion (e.g., typically about 3 to 7 days), there is no ability to extend the production phase. Fed-batch culture improves the batch process by providing a bolus or continuous medium feed to replenish consumed medium components. Since fed-batch culture accommodates additional nutrients throughout the run, it allows for higher cell densities (>20x10⁶) compared to batch methods. 6 There is a possibility of achieving increased product potency (depending on cell / ml, medium formulation, cell line, etc.) and increased product potency.

[0046] Unlike batch processing, biphasic culture can be produced and maintained by manipulating feeding strategies and media formulations to distinguish between a period of interruption or slow cell growth (production phase) and a period of cell proliferation to achieve the desired cell density (growth phase). Therefore, fed-batch culture has the potential to achieve higher product potency compared to batch culture. Generally, batch methods are used during the growth phase and fed-batch methods during the production phase, but fed-batch feeding strategies can be used throughout the entire process. However, unlike batch processes, bioreactor volume is a limiting factor that restricts the amount of feed. Also, as with batch methods, the accumulation of metabolic byproducts leads to reduced culture size, limiting the duration of the production phase to approximately 1.5 to 3 weeks. Fed-batch culture is discontinuous, and harvesting typically occurs when metabolic byproduct levels or culture viability reach a pre-measured level.

[0047] Perfusion methods offer a promising improvement over batch and fed-batch methods by adding fresh medium and simultaneously removing used medium. Typical large-scale commercial cell culture strategies strive to reach high cell densities (greater than 20 e¹⁶ cells / mL), where biomass accounts for nearly one-third to more than half of the reactor volume. With perfusion culture, >1 x 10⁶ 8Extreme cell densities of cell / mL have been achieved, and even higher densities are predicted. A typical perfusion culture is initiated by the start of a batch culture lasting 1 to 2 days, continuously, stepwise, and / or intermittently adding fresh feed medium to the culture throughout the growth and production phases of the culture, while simultaneously removing the medium consumed for cell maintenance and additional high molecular weight compounds, e.g., proteins (depending on the filter molecular weight cutoff). Various methods, e.g., sedimentation, centrifugation, or filtration, can be used to remove the consumed medium while maintaining cell density. Perfusion flow rates ranging from a fraction of the daily working volume to several times the daily working volume have been reported.

[0048] The advantage of perfusion methods is that production cultures can be maintained for longer periods than batch or fed-batch methods. However, supporting long-term perfusion cultures, particularly at high cell densities, requires increased media preparation, use, storage, and disposal, as well as greater nutrients; all of these factors make production costs significantly higher compared to batch and fed-batch methods. Furthermore, higher cell densities can lead to problems during production, such as increased gasging, which involves maintaining dissolved oxygen levels, supplying more oxygen, and removing more carbon dioxide. This results in more foam and necessitates changes to antifoaming strategies. Additionally, the effort required to remove excess cell material during harvesting and downstream processing may lead to product loss, and the benefits of increased potency resulting from increased cell mass may be negated.

[0049] The present invention relates to an improved bioreactor comprising any type of bioreactor described above, wherein a sparger / microsparger is replaced by one or more membrane gas delivery modules described herein. The present invention relates, in part, to the surprising discovery that, in the context of a high-density cell culture bioreactor, by replacing a sparger or microsparger with one or more hollow fiber membrane modules inside or outside the bioreactor itself, continuous dissolved oxygen levels at high cell densities are achieved without severely affecting culture vitality during operation. Accordingly, the present invention relates to an improved bioprocess system and bioprocess method for cell culture using an improved bioreactor, for example, a fed-batch or perfusion bioreactor cell culture system for producing monoclonal antibodies or bispecific antibodies, comprising one or more membrane gas delivery modules instead of a sparger- or microsparger-based aeration system, so as to better control the levels of important gases, for example, dissolved O2 levels and dissolved CO2 levels, in bioreactor cell culture, even at high cell densities, without the cells undergoing bubble-induced cell death.

[0050] Generally, the bioreactor of the present invention may include a vessel in which a biological process takes place. The vessel, for example, the vessel (101) of FIG. 1a or the vessel (302) of FIG. 1b, is generally made of an autoclavable and inert material, for example, glass, plastic, or stainless steel, and may or may not be jacketed. In some cases, the vessel may have a relatively small volume, for example, about 0.5 L, 1 L, 2 L, 4 L, 10 L, 20 L, 40 L, or less than 100 L. In some cases, the vessel may have a relatively large volume, for example, 100 L, 200 L, 300 L, 500 L, 1,000 L, 5,000 L, 10,000 L, or more than 30,000 L. The total volume of a suitable low-volume vessel may be, for example, about 0.5 to 5 L, for example, 0.5 L, 1 L, 2 L, 4 L, 10 L, 20 L, 40 L, or 50 L. For example, the total volume of the vessel may be 75 L, 150 L, 300 L, 500 L, 1,000 L, 1,500 L, 3,000 L, or 5,000 L. The aspect ratio (diameter:height) of the vessel may preferably be, for example, about 0.5:1 to about 4:1 or about 0.5:1 to 2:1, for example, about 0.5:1 to 1:1. The present invention takes into account the use of any suitable bioreactor volume or aspect ratio, which is not limited to those indicated above.

[0051] A shaft (e.g., shaft (104) of FIG. 1a) extends into a vessel, and an impeller (e.g., impeller (104) of FIG. 1a) is mounted on the distal end of the shaft. As described in detail below, the impeller creates a circulating flow in the liquid (e.g., cell culture medium) within the vessel, as indicated by the arrow surrounding the impeller. Generally, the shaft is driven by a motor.

[0052] The bioreactor may include any other desirable bioreactor components and features, including a pump, a container for alternative growth medium, a container for nutrients, a collection or harvesting module (e.g., the harvesting module (313) in FIG. 1b), a gas source or a plurality of gas sources, and appropriate valve, tubing, and mixing devices. The bioreactor considered herein may include a dissolved oxygen probe, a dissolved carbon dioxide probe, a pH probe, and an oxidation-reduction (ORP) probe (see FIG. 1c and 1d) for monitoring these parameters, and a sampling probe for sampling or harvesting the contents of the container. A condenser for condensing volatiles may also be provided.

[0053] The bioreactors considered herein generally include a controller configured to control process parameters by receiving signals from various monitoring devices (e.g., probes shown in FIGS. 1c and 1d) and adjusting the process parameters based on this data. The controller may be, for example, a programmable logic controller (PLC) with an operator interface. The controller may optionally be configured to control multiple vessels.

[0054] In some implementations, gas delivery is made through the shaft of the impeller. For example, the shaft may include a bore through which the gas is delivered and one or more orifices through which the gas exits into a vessel.

[0055] The bioreactors considered herein may also include a number of other features to enhance the biological process. For example, the vessel may be cooled (or heated) by, for example, a water jacket or other cooling / heating system to maintain a desired process temperature. The vessel may also be heated by any suitable heating system, including one configured outside the growth vessel or placed inside the growth vessel. A foam detector may be provided, and an antifoaming agent delivery system may be included to deliver an antifoaming agent to the vessel in the event of excessive foam formation. In some implementations, the bioreactor may be sterilized in situ by, for example, an automatic steam injection system. Various access ports may be provided on the vessel.

[0056] The bioreactor considered herein may also include one or more membrane gas transfer modules, said modules may be located within the bioreactor vessel or outside the vessel, but communicate with the flow path of the cell culture medium. For example, the flow path (314) of FIG. 1b provides a two-module system (309a and 309b) for gas exchange. An embodiment is illustrated in FIG. 1b.

[0057] FIG. 1b illustrates a schematic diagram of an embodiment of the bioreactor disclosed herein. In the embodiment, the improved bioreactor (300) comprises one or more externally located membrane gas transfer modules (309), wherein the modules are supplied with cell culture along a series of flow paths (314) from / to the bioreactor by a pump (312). The first membrane gas transfer module (309b) has a gas inlet (310b) and a gas outlet (311b). The second membrane gas transfer module (309a) also has a gas inlet (310a) and a gas outlet (311a). The pump (312) moves the cell culture from the bioreactor (300) along the flow path (314) (i.e., recirculation loop) through the first membrane gas transfer module (309b) and then through the second membrane gas transfer module (309a), allowing the cell culture to interact with the gas flowing through the membrane module, which is introduced at the gas inlet and exits through the outlet port. The gas interacts with the cell culture by passing through the gas-permeable membrane of the module, which separates the gas flow zone from the cell culture flow path. This module can add a specific gas (e.g., oxygen) without bubbling and / or remove another gas (e.g., CO2) from the bioreactor cell culture. The cell culture processed by the module along the flow path (314) is returned to the bioreactor (300). The precise configuration shown in FIG. 1b is not intended to limit other available configurations considered in the present invention. It may include a computer controller for controlling the flow of O2 gas and CO2 gas into the membrane to maintain dissolved O2 and CO2 at desirable concentrations in the bioreactor.

[0058] During operation, temperature can be a critical factor in maintaining cell culture viability. Since different biological materials operate optimally at different temperatures, temperature depends on the characteristics of the culture and the expressed products; therefore, the temperature may vary slightly during bioreactor operation. The temperature may be about -5 to 120°C, -5 to 0°C, about 0 to 100°C, about 0 to 50°C, about 0 to 20°C, about 20 to 120°C, about 50 to 120°C, about 90 to 120°C, about 10 to 45°C, about 10 to 35°C, about 10 to 25°C, about 20 to 55°C, about 30 to 55°C, about 40 to 55°C, about 15 to 45°C, about 17 to 42°C, about 20 to 40°C, about 20 to 30°C, or about 30 to 40°C, and about -5°C, 0°C, 5°C, 10°C, 15°C, 17°C, 20°C, 25°C, 28°C, 30°C, 35°C, It may be 37℃, 40℃, 42℃, 45℃, 50℃, 60℃, 70℃, 80℃, 90℃, 100℃, 110℃, or 120℃.

[0059] Cells in a bioreactor can be grown at an appropriate cell density. As used herein, "cell density" refers to the number of cells in a given volume of culture medium. "Vivid cell density" refers to the number of living cells in a given volume of culture medium, measured by a standard viability test (e.g., the trypan blue dye exclusion method). The trypan blue dye exclusion test is used to measure the number of viable cells present in a cell suspension. This is based on the principle that living cells possess an intact cell membrane that excludes a specific dye, such as trypan blue, whereas dead cells do not. In this test, the cell suspension is simply mixed with the dye and then visually inspected (or using automated imaging-based equipment) to determine whether the cells absorb or exclude the dye.

[0060] The desirable viable cell density maintained during the transition between the growth and production stages and during the production stage is to provide a packed cell volume of 35% or less. In one embodiment, the viable cell density is at least about 10x10 6 It is viable cells / mL. In another embodiment, the viable cell density is 20x10 6 Viable cells / mL, 30x10⁻⁶ 6 Viable cells / mL, 40x10 6 Viable cells / mL, 50x10 6 Viable cells / mL, 60x10⁻⁶ 6 Viable cells / mL, 70x10 6 Viable cells / mL, 80x10⁻⁶ 6 Viable cells / mL, 90x10⁻⁶ 6 Viable cells / mL, 100x10⁻⁶ 6 Viable cells / mL, 110x10 6 Viable cells / mL, 120x10⁻⁶ 6 Viable cells / mL, 130x10⁻⁶ 6 Viable cells / mL, 140x10⁻⁶ 6 Viable cells / mL, 150x10⁻⁶ 6 Viable cells / mL, 160x10⁻⁶ 6 Viable cells / mL, 170x10⁻⁶ 6 Viable cells / mL, 180x10⁻⁶ 6 Viable cells / mL, 190x10⁻⁶ 6 Viable cells / mL, 200x10⁻⁶ 6 Viable cells / mL, 210x10⁻⁶ 6 Viable cells / mL, 220x10⁻⁶ 6 Viable cells / mL, 230x10⁻⁶ 6 Viable cells / mL, 240x10⁻⁶ 6 Viable cells / mL or 250x10⁻⁶ 6 Viable cells / mL can be reached. In one embodiment, the viable cell density is at least about 10x10 6 Up to 70x10 6 It is viable cells / mL. In one embodiment, the viable cell density is at least about 10x10 6 Up to 60x10 6It is viable cells / mL. In one embodiment, the viable cell density is at least about 10x10 6 Up to 50x10 6 It is viable cells / mL. In one embodiment, the viable cell density is at least about 10x10 6 Up to 40x10 6 It is viable cells / mL. In a preferred embodiment, the viable cell density is at least about 10x10 6 Up to 30x10 6 It is viable cells / mL. In another preferred embodiment, the viable cell density is at least about 10x10 6 Up to 20x10 6 It is viable cells / mL. In another preferred embodiment, the viable cell density is at least about 20 x 10⁻⁶ 6 Up to 30x10 6 It is viable cells / mL. In another preferred embodiment, the viable cell density is at least about 20 x 10⁻⁶ 6 to at least about 25x10 6 Viable cells / mL, more preferably at least about 20x10 6 It is viable cells / mL. In another embodiment, the viable cell density is at least about 20 x 10 6 Up to 120x10 6 Viable cells / mL, at least about 40x10 6 Up to 140x10 6 Viable cells / mL, at least about 60x10 6 Up to 160x10 6 Viable cells / mL, at least about 80x10 6 Up to 180x10 6 Viable cells / mL or at least about 100x10 6 Up to 200x10 6 It is the number of viable cells / mL.

[0061] Membrane module

[0062] The present invention relates to a bioreactor comprising one or more membrane gas transfer modules for regulating, controlling, or otherwise performing gas exchange processes that are included or required during the operation of the bioreactor, for example, a perfusion or fed-batch bioreactor. Preferably, the bioreactor of the present invention does not introduce bubbles into the cell medium as a result of membrane-based mass transfer processes. The bioreactor of the present invention is suitable for high-density cultures, for example, cell density of at least about 20 x 10 6 Up to 120x10 6 Viable cells / mL, at least about 40x10 6 Up to 140x10 6 Viable cells / mL, at least about 60x10 6 Up to 160x10 6 Viable cells / mL, at least about 80x10 6 Up to 180x10 6 Viable cells / mL or at least about 100x10 6 Up to 200x10 6 It is suitable for the growth of a culture with viable cells / mL. The gas exchange process preferably includes the addition of gas to the cell culture (e.g., addition of O2) and the removal of gas from the cell culture (e.g., stripping of CO2), without introducing bubbles into the culture medium.

[0063] Furthermore, the present invention relates to a high-density cell culture method comprising using one or more membrane gas transfer modules to regulate, control, or otherwise perform a gas exchange process that is included or required during the operation of a high-density cell culture bioreactor, e.g., a perfusion or fed-batch bioreactor. Preferably, the bioreactor of the present invention does not introduce bubbles into the cell medium as a result of membrane-based mass transfer processes. The cell culture method of the present invention relates to a high-density culture, e.g., a cell density of at least about 20 x 10 6 Up to 120x10 6 Viable cells / mL, at least about 40x106 Up to 140x10 6 Viable cells / mL, at least about 60x10 6 Up to 160x10 6 Viable cells / mL, at least about 80x10 6 Up to 180x10 6 Viable cells / mL or at least about 100x10 6 Up to 200x10 6 It is suitable for the growth of a culture of viable cells / mL. The gas exchange process preferably includes the addition of gas to the cell culture (e.g., addition of O2) and the removal of gas from the cell culture (e.g., stripping of CO2) without introducing bubbles into the culture medium.

[0064] As used herein, the term “membrane gas transfer module” refers to an apparatus comprising a sealed housing having a first inlet and a first outlet and defining a first flow path, and at least one membrane contained within the housing connected to at least a second inlet and a second outlet and defining a second flow path, wherein the first flow path and the second flow path are separated by the membrane. An exemplary membrane gas transfer module is illustrated in FIG. 1e, which illustrates a generalized schematic diagram of a membrane gas transfer module (600) that may be used in connection with the improved bioreactor of the present invention. In a general but non-limiting configuration, the membrane module of the present invention may comprise a hollow fiber bundle (601) of gas-permeable hollow fiber tubes (602), said tubes which are secured together by a potting or seal (603) and placed inside a housing or shell (605), and an inlet cap (604) is fitted at each end so as to introduce a flow of one or more gases through the interior of each hollow fiber. The housing of the present invention may also include one or more inlet / outlet ports (606 and 607) for a flow path of cell culture, said flow path enters through one port, flows through the housing within the space surrounding the hollow fiber, and then exits through the outlet port. In practice, the flow path of cell culture is pumped into one inlet on the housing, flows through the housing around the outer space surrounding each hollow fiber of the hollow fiber bundle, and exits through the outlet port. At the same time, inside the housing, the cell culture comes into contact with the outside of the gas-permeable membrane of the hollow fiber bundle.

[0065] In one embodiment, the membrane module may include a first flow path, said path may be for a cell culture medium, said medium enters through a first inlet crossing the first flow path and exits through a first outlet. The membrane module of the present invention may include a second flow path for one or more gases or gas mixtures. A gas enters through a second inlet, passes through a second flow path, and then exits through a second outlet. While the gas passes through the second flow path, the gas may permeate from the second flow path through the membrane into the cell culture of the first flow path. Additionally, a gas dissolved in the cell culture of the first flow path may permeate through the membrane and pass into the second flow path. The outlet of the second flow path may be indicated as a gas "outlet" port.

[0066] FIG. 2 illustrates another aspect of the flow path of the membrane module used herein. This figure illustrates an aspect of a membrane gas delivery module (800) that can be used in connection with the improved bioreactor described herein. The module of the present invention includes a “shell-side-in” inlet (801) for receiving cell culture medium, said medium traversing the entire housing or shell of the space surrounding each of the hollow fibers of the hollow fiber bundle. The culture medium eventually exits the housing through a “shell-side-out” outlet port (802). In this example, there are two outlet ports; however, any number of outlet ports may be used. The module of the present invention includes one or more “tube (lumen)-side-in” inlet ports (804) for receiving one or more gases or gas mixtures, said gas or gas mixtures entering into the lumen or internal space of each of the hollow fibers of the hollow fiber bundle. Subsequently, the gas exits through one or more "tube (lumen) side-out" outlet ports (803) along the length of the hollow fiber. This configuration establishes both a "gas flow zone" within the internal space of the hollow fiber's lumen and a "medium or cell culture flow zone," which is a space located outside the hollow fiber but confined within the shell or house. The gas in the gas flow zone can pass through the membrane and move into the medium flow zone. Alternatively, dissolved gas (e.g., CO2) can pass through the hollow fiber membrane into the gas flow zone and exit the module to the "exhaust section" through the gas outlet ports.

[0067] FIG. 3 also provides exemplary forms of flow paths used in gas transfer modules. In particular, the figure illustrates various configurations of gas flow paths (arrows marked "*") and cell culture medium flow paths (arrows marked "**") in general membrane gas transfer modules of configurations A, B, and C. Ports marked "x" are blocked. As used herein, the term "membrane" refers to a layer of material through which one substance (e.g., gas) passes while blocking another substance (e.g., liquid). Its selectivity may depend on particle size, the state of the material (liquid vs. gas), or solubility. Additionally, separation occurs when there is a driving force, for example, a difference in pressure, temperature, or concentration between one side of the membrane and the other. Membranes include "dense or non-porous membranes" and "porous membranes."

[0068] As used herein, the terms “dense membrane” or “non-porous membrane” refer to solid materials that are free of pores or voids. Examples include polymers (e.g., silicon or polydimethylsiloxane (PDMS)), metals (e.g., palladium), and ceramics. A dense membrane allows a substance to pass through the membrane via solution and diffusion processes, and for the substance to dissolve into the membrane and pass to the other side. For example, silicon can form a dense membrane. Because silicon is dense (non-porous) and liquids cannot move through the membrane entirely, it can be used in liquid contact applications with any compatible liquid, regardless of surface tension. Additionally, dense membranes provide a means of separating gases due to the difference in gas permeability of silicon.

[0069] As used herein, the term "porous membrane" refers to a solid material having pores or holes of a specific size or size range. Such membranes are separated by size exclusion: materials larger than the pores do not pass through, while materials smaller than the pores pass through.

[0070] As used herein, the term "asymmetric membrane" consists of a single material, often porous, having different characteristics (e.g., pore size) from one side to the other. These features result in "narrower" selectivity at the surface and reduce limitation as the material passes through the membrane matrix.

[0071] The term "composite membrane" as used herein is composed of one or more materials and often consists of a thin selective layer of dense material applied to a porous support layer.

[0072] The term "permeability coefficient" used herein in relation to membranes is a parameter defined as the gas transport flux (gas permeability per unit area) per unit membrane thickness per unit membrane penetration driving force.

[0073] In various embodiments, the membrane gas transfer module of the present invention comprises one or more silicon membranes. Silicon, also known as polydimethylsiloxane (PDMS), is one of the most gas-permeable dense polymeric membrane materials available. Gases pass through silicon via a solution / diffusion mechanism, and gas permeability is directly proportional to the product of gas solubility and the diffusion rate of the gas dissolved in silicon. The permeability coefficient is a parameter defined as the gas transport flux (gas permeability per unit area) per unit membrane thickness per unit membrane penetration driving force. Permeability coefficients for various gases and vapors in silicon are shown in the table below.

[0074] [Table 1]

[0075]

[0076] It can be seen that the gas transfer rate across a membrane is proportional to the gas permeability coefficient, membrane surface area, and the difference in gas partial pressure across the permeable membrane, and inversely proportional to the membrane thickness. Therefore, gas transfer through a membrane increases with an increase in the gas permeability coefficient, an increase in the surface area, an increase in the gas partial pressure across the permeable membrane, and a decrease in the membrane thickness.

[0077] In certain embodiments, the membrane used herein may be porous, e.g., nanoporous, mesopolar, or microporous, or may have a combination of nanoscale and / or mesoscale and / or microscale pores. The porosity of the nanoporous solid or gel may be about 40 to 90%, about 40 to 75%, about 40 to 60%, about 50 to 90%, about 60 to 90%, about 70 to 90%, about 50 to 80%, or about 60 to 70%, and may be about 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, or 90%. The average diameter of the pores may be about 1 nm to 10 µm, about 1 nm to 1 µm, about 1 to 500 nm, about 1 to 100 nm, about 1 to 50 nm, about 1 to 10 nm, about 100 nm to 10 µm, about 500 nm to 10 µm, about 1 to 10 µm, about 10 nm to 1 µm, about 50 to 500 nm, or about 100 to 200 nm, and about 1 nm, 5 nm, 10 nm, 15 nm, 20 nm, 25 nm, 30 nm, 35 nm, 40 nm, 45 nm, 50 nm, 75 nm, 100 nm, 150 nm, 200 nm, 250 nm, 300 nm, 350 nm, 400 nm, 450 nm, 500 nm, It may be 600 nm, 700 nm, 800 nm or 900 nm or about 1 µm, 2 µm, 3 µm, 4 µm, 5 µm, 6 µm, 7 µm, 8 µm, 9 µm or 10 µm.

[0078] The thickness of the film used herein may be any suitable thickness. In various embodiments, the thickness may be about 0.1 to 10 mm, about 0.1 to 5 mm, about 0.1 to 2 mm, about 0.1 to 1 mm, about 1 to 10 mm, about 5 to 1.0 mm, about 0.5 to 5 mm, about 1 to 5 mm, or about 1 to 2 mm, and may be about 0.1 mm, 0.2 mm, 0.3 mm, 0.4 mm, 0.5 mm, 0.6 mm, 0.7 mm, 0.8 mm, 0.9 mm, 1 mm, 1.5 mm, 2 mm, 2.5 mm, 3 mm, 3.5 mm, 4 mm, 4.5 mm, 5 mm, 6 mm, 7 mm, 8 mm, 9 mm, or 10 mm. When fabricating the membrane, the distribution of cells within the nanoporous material may be approximately homogeneous or heterogeneous. Additionally, the membrane may contain a mixture of pores of different sizes.

[0079] In one embodiment, the bioreactor of the present invention may be configured as a hollow fiber gas transfer module, for example, a PERMSELECT® silicon hollow fiber membrane module or a module having similar or equivalent properties. The hollow fibers constitute a self-supporting and intrinsically stable membrane structure capable of withstanding a high pressure difference between the inside and outside of the hollow fiber membrane. The hollow fiber membranes are generally packaged in membrane modules, in which thousands of hollow fibers are bundled in a very compact volume and sealed or potted within a housing as shown in the drawings below. An exemplary hollow fiber module is illustrated in FIGS. 1e and FIGS. 2. Consequently, the sum of the surface areas of each individual hollow fiber membrane constitutes the total membrane area of ​​the module, which makes it clear how it is possible to achieve a high membrane surface density with hollow fiber membranes.

[0080] The membrane module will generally have inlet and outlet ports that fluidly communicate with the interior of all manifolded hollow fibers (also known as tube sides) at both ends of the fiber bundle. For example, see Fig. 1e. Similarly, the membrane module will have one or more ports that fluidly communicate with the exterior of the hollow fibers or the shell sides. During operation, as illustrated in Fig. 2, the side of the hollow fiber (shell or tube) through which the gas or liquid must flow will depend on the specific application for the membrane module and is selected to maximize membrane module performance. For example, as illustrated in Fig. 2, in membrane gas separation, a feed mixture of gases enters the membrane module through the inlet port into the tube side and flows through the interior of the hollow fiber membrane. Gas species of the mixture with higher permeability are transported across the walls of the hollow fiber membrane at a faster speed, leaving behind less permeable species. The transported gas is referred to as permeate. On the shell side, a vacuum may be applied, or a swept gas (or liquid) may flow inward to transport the permeate. What exits the outlet on the side of the tube is a residue constituting a gas mixture with a higher concentration of less permeable gas species.

[0081] In various embodiments, the module of the present invention can be used for adding and / or removing dissolved gases into or from a liquid. During operation, a liquid stream flows from one side of the membrane and a gas mixture flows from the other side of the membrane (or a vacuum is applied). Since each gas species flows from the membrane side with higher partial pressure to the side with lower partial pressure, both sides tend to reach equilibrium. Therefore, the dissolved gases in the liquid stream flowing through the module can be controlled by controlling the applied gas mixture (or vacuum). This principle can be used to control the levels of dissolved oxygen and carbon dioxide in cell cultures.

[0082] cell

[0083] The improved bioreactor described herein can be used in microbial fermentation and / or cell culture biological processes using various types of microorganisms and cells. In principle, the cells that can be used are any cells known to those skilled in the art and have the ability to produce biological products. The cells are eukaryotic cells, for example, filamentous fungi, for example, Aspergillus niger , Aspergillus oryzae , Trichoderma reesei , Penicilliumi chrysogenum , yeast, for example, Saccharomyces cerevisiae , Kluyveromyces lactis , Phaffia rhodozyma ), Pichia Yeast inside, for example, Pichia pastoris ), prokaryotes, for example, Escherichia coli ), Bacillus sp, for example, B. licheniformis ), B. subtilis ), B. amyloliquefaciens ), B. aikalophilus ), Streptomyces sp., Corynebacterium glutamicum ), Pseudomonas It may be sp. Examples of eukaryotic cells are described, for example, in the literature [Chu, L., Robinson, DK, (2001) Curr. Opinion Biotechn., vol. 12, p. 180-187]. Preferably, the cells used in the method of the present invention are animal cells, particularly mammalian cells. Examples of mammalian cells are CHO (Chinese hamster ovary) cells, hybridoma, BHK (young hamster kidney) cells, myeloma cells, human cells, for example, HEK-293 cells, human lymphoblast cells, E1 indeterminate HER cells, mouse cells, for example, NS0 cells.

[0084] Examples of cell types for culture and harvesting using the bioreactor of the present invention include, but are not limited to, monoclonal antibody-secreting hybridoma cells derived from mice, rats, rabbits, or humans for medical, research, or commercial purposes, eukaryotic cells, biochemical markers, recombinant peptides or nucleotides of sequences of interest, proteins, yeast, insect cells, stable or virus-infected avian cells or mammalian cells, e.g., CHO cells, monkey cells, lysis products, etc.

[0085] badge

[0086] The improved bioreactor described herein may be used with any suitable cell culture or microbial growth medium. Methods for selecting and optimizing a suitable cell culture medium or microbial medium are widely known to those skilled in the art and may vary depending on many factors, including the type of bioprocessor (e.g., fed-batch, perfusion, continuous flow), the type of cell line or microbial cell used, and the specific biological product to be expressed.

[0087] A critical step in cell culture is selecting an appropriate growth medium for in vitro culture. Growth media, or culture media, are liquids or gels designed to support the growth of microorganisms, cells, or small plants. Cell culture media generally contain appropriate energy sources and compounds that regulate the cell cycle. Common culture media consist of amino acids, vitamins, inorganic salts, glucose, and serum supplements, serving as sources of growth factors, hormones, and adhesion factors. In addition to nutrients, they also help maintain pH and osmotic pressure.

[0088] The biological process is generally carried out in an aqueous growth medium, which may contain a nitrogen source or other nutrient sources, such as urea, along with vitamins, trace minerals, and metals. Generally, it is desirable for the growth medium to be sterile or at least have a low microbial load, for example, a bacterial count. Sterilization of the growth medium can be performed in any desired manner. However, in a preferred embodiment, sterilization is achieved by irradiating the growth medium or its individual components before mixing. The radiation dose is generally kept as low as possible to obtain appropriate results while minimizing energy consumption and associated costs.

[0089] Animal cells can be cultured in either completely natural media or artificial / synthetic media along with some natural products. Natural media consist solely of naturally occurring biological fluids. Natural media are highly useful and convenient for culturing a wide range of animal cells. The biggest disadvantage of natural media is their low reproducibility due to a lack of knowledge regarding their precise composition. Artificial or synthetic media are prepared by adding nutrients (both organic and inorganic), vitamins, salts, O2 and CO2 gas phases, serum proteins, carbohydrates, and cofactors. Different artificial media have been designed to provide one or more of the following purposes: 1) immediate viability (balanced salt solutions with specific pH and osmotic pressure); 2) extended viability (balanced salt solutions supplemented with various organic compounds and / or serum formulations); 3) indefinite growth; and 4) specialized functions.

[0090] Artificial media are generally grouped into four categories: (1) serum-containing media; (2) serum-free media; (3) chemically limited media; and (4) protein-free media.

[0091] In serum-containing media, fetal bovine serum is the most common supplement in animal cell culture media. Fetal bovine serum is used as an inexpensive supplement to provide optimal culture media. Serum provides carriers or chelators for unstable or water-insoluble nutrients, hormones, growth factors, and protease inhibitors, and binds to and neutralizes toxic moiety.

[0092] In the case of serum-free media, the presence of serum in the medium can be associated with many disadvantages and lead to serious misunderstandings in immunological research. Many serum-free media have been developed. These media are generally specifically formulated to support the culture of single-cell types, such as Thermo Fisher Scientific’s Knockout Serum Replacement and Knockout DMEM for stem cells, and contain limited amounts of purified growth factors, lipoproteins, and other proteins that are typically provided by serum. These media are also referred to as 'limited culture media' because their components are known.

[0093] In chemically limited media, these media contain ultrapure inorganic and organic components free from contamination and may also contain pure protein additives such as growth factors. Their components are produced from bacteria or yeast by genetic engineering with the addition of vitamins, cholesterol, specific amino acids, and fatty acids.

[0094] Protein-free media are devoid of protein. Compared to serum-supplemented media, the use of protein-free media can, in some cases, promote superior cell growth and protein expression, and facilitate downstream purification of all expressed products. Formulations such as MEM and RPMI-1640 are protein-free, and protein supplements are provided as needed.

[0095] Additionally, you will recognize that culture media contain a mixture of amino acids, glucose, salts, vitamins, and other nutrients, and can be obtained from commercial suppliers in powder or liquid form. The requirements for these components vary by cell line, and these differences are partly responsible for the wide number of media formulations. Each component performs a specific function, including the following:

[0096] Buffering Systems: pH control is critical for optimal culture conditions and is generally achieved using natural or chemical buffering systems. In natural buffering systems, gaseous CO2 is balanced with the CO3 / HCO3 content of the culture medium. Cultures with natural buffering systems should generally be maintained in an air atmosphere containing 5 to 10% CO2, maintained by a CO2 incubator. Natural buffering systems are inexpensive and non-toxic.

[0097] Chemical buffering systems are also used. Chemical buffering using the zwitterion HEPES provides excellent buffering capacity in the pH range of 7.2 to 7.4 and does not require a controlled gas atmosphere. HEPES is relatively expensive for some cell types and is toxic at high concentrations. HEPES has also been shown to significantly increase the sensitivity of the medium to phototoxic effects caused by exposure to fluorescent light.

[0098] Cell culture media may also contain pH indicators such as phenol red. Most commercially available culture media include phenol red as a pH indicator, allowing for continuous monitoring of pH. During cell growth, the color of the medium changes as pH fluctuates due to metabolites released from the cells. At low pH levels, phenol red turns medium yellow, while at high pH levels, it turns medium purple. The medium is bright red at pH 7.4, which is the optimal pH value for cell culture.

[0099] The cell culture media used in this institution may also contain inorganic salts. Inorganic salts in the medium help maintain osmotic balance and aid in regulating membrane function by providing sodium, potassium, and calcium ions. Cultures may also benefit from the presence of amino acids. In particular, essential amino acids must be included in the culture medium because cells cannot synthesize them themselves. Essential amino acids are required for cell proliferation, and their concentration determines the maximum achievable cell density. L-glutamine, an essential amino acid, is particularly important. L-glutamine provides nitrogen to NAD, NADPH, and nucleotides, and serves as a secondary energy source for metabolism. Since L-glutamine is an unstable amino acid that converts into a form unusable by cells over time, it may be added to the medium immediately before use. Because the degradation of L-glutamine leads to the accumulation of ammonia, which can have harmful effects on some cell lines, caution should be exercised when adding more L-glutamine than required by the original medium formulation. L-glutamine concentrations in mammalian cell culture media vary from 0.68 mM in medium 199 to 4 mM in Dulbecco's modified Eagle medium. Invertebrate cell culture media can contain as high as 12.3 mM L-glutamine. Supplements such as Glutamex can replace glutamine for longer-term, more stable, and slower cell cultures.

[0100] Non-essential amino acids may be added to the culture medium to replace amino acids depleted during growth. Supplementing the medium with non-essential amino acids promotes growth and extends cell viability.

[0101] Carbohydrates can also be added to cell culture media. Carbohydrates in the form of sugars are a major energy source. Most media contain glucose and galactose, but some contain maltose and fructose.

[0102] The cell culture media used herein may also contain proteins and peptides. The most commonly used proteins and peptides are albumin, transferrin, and fibronectin. These are particularly important in serum-free media. Serum is a rich source of proteins and contains albumin, transferrin, aprotinin, petuin, and fibronectin. Albumin is the major protein that binds water, salts, free fatty acids, hormones, and vitamins from the blood and transports them between tissues and cells. The binding capacity of albumin is suitable for removing toxic substances from cell culture media.

[0103] The cell culture media used at this institution may also contain protective agents such as aprotinin. Aprotinin is stable at neutral and acidic pH and is resistant to high temperatures and degradation by proteolytic enzymes. Aprotinin also has inhibitory activity against several serine proteases, such as trypsin. Petuin is a glycoprotein found in fetal and neonatal serum at higher concentrations than in adult serum. Petuin is also an inhibitor of serine proteases. Fibronectin plays a key role in cell adhesion. Transferrin is an iron transport protein responsible for supplying iron to the cell membrane.

[0104] The cell culture media used at this institution may also contain vitamins and trace elements. Many vitamins are essential for cell growth and proliferation. Since vitamins cannot be synthesized by cells in sufficient quantities, they are important supplements required for tissue culture. Again, while serum is the primary source of vitamins in cell culture, media are also rich in other vitamins to make them suitable for specific cell lines. Group B vitamins are most commonly added to promote growth. Trace elements are often supplemented in serum-free media to replace those typically found in serum. Trace elements such as copper, zinc, selenium, and tricarboxylic acid intermediates are chemical elements required in small amounts for proper cell growth. These micronutrients are essential for many biological processes, such as maintaining enzyme function.

[0105] The complete growth medium recommended for specific cell lines may require additional components not present in the basic medium and serum. These supplementary components help maintain proliferation and sustain normal cellular metabolism, such as hormones, growth factors, and signaling molecules.

[0106] Growth media may also contain antibiotics. Although antibiotics are not essential for cell growth, they are often used to control the growth of bacterial and fungal contaminants. Since antibiotics can mask contamination by Mycoplasma and resistant bacteria, the routine use of antibiotics for cell culture is not recommended. Additionally, antibiotics may interfere with the metabolism of sensitive cells.

[0107] The selection of the culture medium depends on the type of cells being cultured, the purpose of culture, and the resources available in the laboratory. Since different cell types have very specific growth requirements, the medium best suited for each cell type must be determined experimentally. Generally, it is recommended to start with MEM for adherent cells and RPMI-1640 for suspension cells. Examples of common cell culture media can be found commercially (SIGMA®, ATCC®, LIFE TECHNOLOGIES®) and are as follows:

[0108] Eagle's Minimum Essential Medium (EMEM): EMEM was one of the first widely used media and was formulated by Harry Eagle from Simple Basic Medium (BME). EMEM contains a balanced salt solution, non-essential amino acids, and sodium pyruvate. It is formulated with a reduced sodium bicarbonate concentration (1,500 mg / l) for use with 5% CO2. Because EMEM is a non-conjugated medium, it is typically fortified with additional supplements or higher levels of serum to make it suitable for a wide range of mammalian cells.

[0109] Dulbecco Modified Eagle Medium (DMEM). DMEM has nearly twice the amino acid concentration and four times the amount of vitamins compared to EMEM, and also contains ferric sodium, sodium pyruvate, and some auxiliary amino acids. The original formulation contains 1,000 mg / L of glucose and was first reported for culturing embryonic mouse cells. Further modification to 4,500 mg / L of glucose has proven to be optimal for various types of cell culture. DMEM is a basic medium and does not contain proteins or growth promoters. Therefore, it requires supplementation to become a "complete" medium. It is most commonly supplemented with 5 to 10% fetal bovine serum (FBS). Since DMEM uses a sodium bicarbonate buffer system (3.7 g / L), it requires artificial levels of CO2 to maintain the necessary pH. Powdered media are formulated without sodium bicarbonate because they tend to release gases in a powdered state. When dissolving the powdered medium in water, 3.7 g / L of sodium bicarbonate must be added. DMEM was initially used for the culture of mouse embryonic stem cells. DMEM has been found to be widely applicable to primary mouse and chicken cells, as well as to studies on viral plaque formation and contact inhibition.

[0110] RPMI-1640. RPMI-1640 is a universal medium with extensive applications for mammalian cells, particularly hematopoietic cells. RPMI-1640 was developed at the Roswell Park Memorial Institute (RPMI) in Buffalo, New York. As a variant of McCoy 5A, RPMI-1640 was developed for the long-term culture of peripheral blood lymphocytes. RPMI-1640 utilizes a bicarbonate buffering system, which distinguishes it from most mammalian cell culture media, which are standard pH 8 formulations. RPMI-1640 supports the growth of a wide variety of cells in suspension and grows as a monolayer. When properly supplemented with serum or appropriate serum substitutes, RPMI-1640 has extensive applications for mammalian cells, including novel human lymphocyte cultures, fusion protocols, and the growth of hybrid cells.

[0111] The cell culture media and microbial growth media described above are not intended to limit the range and scope of usable media that can be used in the present invention. A person skilled in the art may consider appropriate media options depending on the overall situation and make an appropriate selection.

[0112] In addition, depending on the type, the bioprocess system may include other components that facilitate the bioprocess. For example, various enzymes and surfactants may be added.

[0113] For example, enzymes, such as celloviases and cellulases, are used in some biological processes. Celloviases include celloviases derived from Aspergillus niger sold under the trade name NOVOZYME 188™. Cellulases may be of fungal or bacterial origin. Cellulases Bacillus , Pseudomonas , Humicola , Fusarium , Thielavia , Acremonium , Chrysosporium and Trichoderma It contains cellulase from within, Fumikola , Coprinus , Tielavia , Fusarium , Myceliophthora , Acremonium , Cephalosporium , Scytalidium , Penicillium or Aspergillus Cellulase from species (see, e.g., EP 458162), particularly species Humicola insolens ( Scytallidium thermophilum Reclassified as, for example, see U.S. Patent No. 4,435,307), Coprinus cinereus , Fusarium oxysporum , Myceliophthora thermophila , Meripilus giganteus , Thielavia terrestris , Acremonium sp., Acremonium persicinum , Acremonium acremonium , Acremonium brachypenium , Acremonium dichromosporum , Acremonium obclavatum , Acremonium pinkertoniae , Acremonium roseogriseum , Acremonium incoloratum and Acremonium furatum Cellulase produced by a strain selected from; preferably a species Fumikola Insolence DSM 1800, Fusarium oxysporum DSM 2672, Mycelioptora thermophilia CBS117.65, Cephalosporium sp. RYM-202, Acremonium sp. CBS 478.94, Acremonium sp. CBS 265.95, Acremonium persicinum CBS169.65, Acremonium Acremonium AHU 9519, Cephalosporium sp. CBS 535.71, Acremonium brachaifenium CBS 866.73, Acremonium dichromosporum CBS 683.73, Acremonium obclavatum CBS 311.74, Acremonium Finkertonia CBS157.70, Acremonium Rosseogriseum CBS134.56, Archremonium Incoloratum CBS146.62 and Archremonium Incoloratum It includes a cellulase selected from CBS146.62. The cellulose-degrading enzyme Chrysosporium , preferably Chrysosporium lucknowense It can also be obtained from strains. In addition, Trichoderma (especially Trichoderma viride , Trichoderma reeseiand Trichoderma koningii ), alkali affinity Bacillus (See, for example, U.S. Patent No. 3,844,890 and EP 458162) and Streptomyces (For example, see EP 458162) may be used.

[0114] Enzyme complexes, for example, the Accellerase® 1500 enzyme complex available from Genencore under the trade name ACCELLERASE®, may be used. The Accellerase 1500 enzyme complex contains several enzyme activities, such as exoglucanase, endoglucanase (2,200 to 2,800 CMC U / g), hemi-cellulase, and beta-glucosidase (525 to 775 pNPG U / g), and has a pH of 4.6 to 5.0. The endoglucanase activity of the enzyme complex is expressed in carboxymethylcellulose active units (CMC U), while the beta-glucosidase activity is reported in pNP-glucoside active units (pNPG U). In one embodiment, a blend of Accellerase® 1500 enzyme complex and NOVOZYME™ 188 celloviase is used.

[0115] The addition of surfactants can increase the speed of some biological processes. Examples of surfactants include nonionic surfactants, such as Tween® 20 or Tween® 80 polyethylene glycol surfactants, ionic surfactants, or amphoteric surfactants. Other suitable surfactants include octylphenol ethoxylates, such as the TRITON™ X series nonionic surfactants commercially available from Dow Chemical. Surfactants may also be added to maintain the product produced in the solution, particularly in high-concentration solutions.

[0116] Bioreactor Products and Purification

[0117] The bioreactors described herein may be used to produce any type of biological product, including vaccines, blood and blood components, allergens, gene therapy components, tissues, and recombinant therapeutic proteins. Biological agents may consist of sugars, proteins, or nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. Therapeutic proteins include, but are not limited to, monoclonal antibodies, bispecific antibodies, enzymes, cytokines, hormones, and fusion proteins.

[0118] The large-scale, economical purification of proteins is becoming an increasingly critical issue in the biotechnology industry. Generally, proteins are produced by cell culture using mammalian or bacterial cell lines engineered to produce the protein of interest by inserting a recombinant plasmid containing the gene for the protein. Since the cell lines used are living organisms, they must typically be supplied with a complex growth medium containing sugars, amino acids, and growth factors derived from animal serum preparations. Separating the desired protein from the mixture of compounds supplied to the cells and the byproducts of the cells themselves to a purity sufficient for use as a human therapeutic agent poses a tremendous challenge.

[0119] In various embodiments, the bioreactors described herein may be used to produce antibody therapeutics. Antibodies within the scope of the invention include anti-HER2 antibodies comprising trastuzumab (HERCEPTIN®) (Carter et al., Proc. Natl. Acad. Sci. USA, 89:4285-4289 (1992), U.S. Patent No. 5,725,856); anti-CD20 antibodies, for example, chimeric anti-CD20 "C2B8" (RITUXAN®) as in U.S. Patent No. 5,736,137, chimeric or humanized variants of 2H7 antibodies as in U.S. Patent No. 5,721,108, B1, or tocitumomab (BEXXAR®); anti-IL-8 (St John et al., Chest, 103:932 (1993) and International Publication No. WO 95 / 23865); Anti-VEGF antibodies comprising humanized and / or affinity-matured anti-VEGF antibodies, e.g., humanized anti-VEGF antibody huA4.6.1 AVASTIN® (Kim et al., Growth Factors, 7:53-64 (1992), International Publication No. WO 96 / 30046 and WO 98 / 45331, published October 15, 1998); anti-PSCA antibody (WO01 / 40309); anti-CD40 antibody comprising S2C6 and its humanized variant (WO00 / 75348); Anti-CD11a (U.S. Patent No. 5,622,700, WO 98 / 23761, Steppe et al., Transplant Intl. 4:3-7 (1991), and Hourmant et al., Transplantation 58:377-380 (1994)); anti-IgE (Presta et al., J. Immunol.151:2623-2632 (1993) and International Publication No. WO 95 / 19181); Claim-CD18 (U.S. Patent No. 5,622,700 issued April 22, 1997, or WO 97 / 26912 published July 31, 1997); Claim-IgE (including E25, E26 and E27; U.S. Patent No. 5,714,338 issued February 3, 1998, or U.S. Patent No. 5,091,313 issued February 25, 1992, WO 93 / 04173 issued March 4, 1993, or International Application No. PCT / US98 / 13410 filed June 30, 1998, U.S. Patent No. 5,714,338); Anti-Apo-2 receptor antibody (WO 98 / 51793 published November 19, 1998); anti-TNF-α antibody comprising cA2(REMICADE®), CDP571, and MAK-195 (U.S. Patent No. 5,672,347 issued September 30, 1997; see Lorenz et al. J. Immunol. 156 (4):1646-1653 (1996) and Dhainaut et al. Crit. Care Med. 23 (9):1461-1469 (1995); anti-tissue factor (TF) (European Patent No. 0420937 B1 granted November 9, 1994); anti-human α4β7 integrin (WO 98 / 06248 published February 19, 1998); Anti-EGFR (chimeric or humanized 225 antibodies such as those in WO 96 / 40210 disclosed on December 19, 1996); anti-CD3 antibodies, e.g., OKT3 (U.S. Patent No. 4,515,893, issued May 7, 1985); anti-CD25 or anti-tac antibodies, e.g., CHI-621 (SIMULECT®) and (ZENAPAX®) (see U.S. Patent No. 5,693,762, issued December 2, 1997); anti-CD4 antibodies, e.g., cM-7412 antibody (Choy et al.Arthritis Rheum 39 (1):52-56 (1996)); anti-CD52 antibodies, e.g., CAMPATH-1H (Riechmann et al. Nature 332:323-337 (1988)); anti-Fc receptor antibodies, e.g., M22 antibody against FcγRI as in Graziano et al. J. Immunol. 155 (10):4996-5002 (1995); Anticancer embryonic antigen (CEA) antibodies, e.g., hMN-14 (Sharkey et al. Cancer Res. 55 (23 Suppl):5935s-5945s (1995); antibodies against breast epithelial cells including huBrE-3, hu-Mc 3, and CHL6 (Ceriani et al. Cancer Res. 55 (23):5852s-5856s (1995); and Richman et al. Cancer Res. 55 (23 Supp):5916s-5920s (1995)); antibodies binding to colorectal carcinoma cells, e.g., C242 (Litton et al. Eur J. Immunol. 26 (1):1-9 (1996)); anti-CD38 antibodies, e.g., AT 13 / 5 (Ellis et al. J. Immunol. 155 (2):925-937 (1995)); anti-CD33 antibodies, e.g., Hu M195 (Jurcic et al. Cancer Res 55 (23 Suppl):5908s-5910s (1995) and CMA-676 or CDP771); anti-CD22 antibodies, e.g., LL2 or LymphoCide (Juweid et al.Cancer Res 55 (23 Suppl):5899s-5907s (1995)); anti-EpCAM antibody, e.g., 17-1a (PANOREX®); anti-GpIIb / IIIa antibody, e.g., apsiximab or c7E3 Fab (REOPRO®); anti-RSV antibody, e.g., MEDI-493 (SYNAGIS®); anti-CMV antibody, e.g., PROTOVIR®; anti-HIV antibody, e.g., PRO542; anti-hepatitis antibody, e.g., anti-Hep B antibody OSTAVIR®; anti-CA 125 antibody OvaRex; anti-idiotype GD3 epitope antibody BEC2; anti-αvβ3 antibody VITAXIN®; anti-human renal cell carcinoma antibody, e.g., ch-G250; ING-1; anti-human 17-1A antibody (3622W94); Anti-human colorectal tumor antibody (A33); anti-human melanoma antibody R24 against GD3 ganglioside; anti-human squamous cell carcinoma (SF-25); and anti-human leukocyte antigen (HLA) antibodies, e.g., Smart ID10 and anti-HLA DR antibody Oncolym (Lym-1), are included but not limited thereto. Preferred target antigens for the antibodies of the present invention are the HER2 receptor, VEGF, IgE, CD20, CD11a, and CD40.

[0120] Any suitable method for purifying bioreactor products is considered. Some proteins can be secreted directly from cells into the surrounding growth medium, while others are produced intracellularly. For the latter proteins, the first step of the purification process involves cell lysis, which can be performed by various methods including mechanical shearing, osmotic shock, or enzymatic treatment. Such disruption releases the entire contents of the cell as a homogenate and also generates subcellular fragments that are difficult to remove due to their small size. These are generally removed by differential centrifugation or filtration. Even on a small scale, the same problem arises with directly secreted proteins due to cell apoptosis and the release of intracellular host cell proteins during the protein production run.

[0121] Once a purified solution containing the protein of interest is obtained, separation from other proteins produced by the cell is generally attempted using a combination of different chromatographic techniques. These techniques separate protein mixtures based on antibody / antigen affinity, charge, degree of hydrophobicity, or size. Since various different chromatographic resins can be used for each of these techniques, a purification scheme for the specific protein in question can be precisely tailored. The key to each of these separation methods is to achieve physical separation by moving proteins down a long column at different speeds, which increases as they pass further down the column, or by allowing them to attach to the separation medium to be eluted differentially by different solvents. In some cases, when impurities specifically attach to the column, the desired protein is separated from the impurities, whereas in other cases, the protein of interest is not separated—that is, the protein of interest is not present in the "flow-through."

[0122] Affinity chromatography, which utilizes specific interactions between the protein to be purified and the immobilized capture agent, may also be an option for some proteins. Protein A is an antibody containing an adsorbent useful for affinity chromatography of proteins, for example, an Fc region. Protein A is a 41 kD cell wall protein from Staphylococcus aureus that binds to the Fc region of the antibody with high affinity (about 10 to 8 M for human IgG).

[0123] Proteins can be purified using controlled pore glass (Sulkowski, E. Protein Purification: Micro to Macro, pgs 177-195 (1987); Chadha et al. Preparative Biochemistry 11 (4):467-482 (1981)) or non-derivative silica (Reifsnyder et al. J. Chromatography 753:73-80 (1996)).

[0124] Proteins purified using the methods described herein are generally produced using recombinant technology. Methods for producing recombinant proteins are described, for example, in U.S. Patents No. 5,534,615 and No. 4,816,567, and are incorporated herein by reference in particular. In a preferred embodiment, the protein of interest is produced in CHO cells (see, for example, WO 94 / 11026). Examples of proteins that can be purified using the processes described herein are described above.

[0125] In certain embodiments (e.g., antibody production), purification can be achieved using a protein A-based means. Protein A immobilized on a solid phase is used to purify proteins containing CH2 / CH3 regions. The solid phase is preferably a column comprising a glass, silica, agarose, or polystyrene surface for immobilizing protein A. Preferably, the solid phase is a controlled-pore glass column or a silicate column. Often, the column is coated with a reagent such as glycerol to prevent non-specific attachment to the column. The PROSEP A™ column, commercially available from Bioprocessing Limited, is an example of a protein A controlled-pore glass column coated with glycerol. Other examples of columns considered herein include the POROS 50 A™ (polystyrene) column or the rProtein A SEPHAROSE FAST FLOW™ (agarose) column.

[0126] The solid phase for protein A chromatography is equilibrated with a suitable buffer. For example, the equilibration buffer may be 25 mM Tris, 25 mM NaCl, 5 mM EDTA, pH 7.1.

[0127] A contaminated preparation derived from recombinant host cells is loaded onto an equilibrated solid phase using a loading buffer that may be identical to the equilibration buffer. As the contaminated preparation flows through the solid phase, the protein is adsorbed to immobilized protein A, and other contaminants (e.g., Chinese hamster ovary protein, CHOP, produced in CHO cells) may bind non-specifically to the solid phase.

[0128] The next step performed sequentially may involve removing contaminants bound to the solid phase, antibody, and / or protein A by washing the solid phase in an intermediate wash step. After loading, the solid phase may be equilibrated with an equilibration buffer before initiating the intermediate wash step. The intermediate wash buffer may comprise a salt and additional compounds, said additional compounds being (a) a detergent (preferably a polysorbate, e.g., polysorbate 20 or polysorbate 80); (b) a solvent (preferably hexylene glycol); and (c) a polymer (preferably PEG). The salt used may be selected depending on the protein of interest, but is preferably an acetate (e.g., sodium acetate) where the antibody is an anti-HER2 antibody such as trastuzumab; or a citrate (e.g., sodium citrate) where the antibody is an anti-IgE antibody such as E26. The amount of salt and the amount of additional compounds in the above composition are amounts such that the combined amount elutes the contaminant(s) without substantially removing the protein of interest. The preferred salt concentration in this washing buffer is about 0.1 to about 2 M, more preferably about 0.2 to about 0.6 M. The useful detergent concentration is, for example, about 0.01 to about 5%, more preferably about 0.1 to 1%, and most preferably about 0.5% when the detergent is polysorbate. The exemplary solvent concentration is about 1 to 40%, preferably about 5 to about 25%. For example, in the examples of the present invention, the preferred concentration of the solvent (hexylene glycol) for E26 was about 20%, whereas for trastuzumab, the preferred concentration of the solvent (again hexylene glycol) was about 10%. If the additional compound is a polymer (e.g., PEG 400 or PEG 8000), its concentration may be, for example, about 1 to about 20%, preferably about 5 to about 15%.

[0129] The eluted protein preparation may undergo additional purification steps before or after the protein A chromatography step. Exemplary additional purification steps include hydroxylapatite chromatography; dialysis; affinity chromatography using antibodies to capture proteins; hydrophobic interaction chromatography (HIC); ammonium sulfate precipitation; anion or cation exchange chromatography; ethanol precipitation; reverse-phase HPLC; chromatography on silica; chromatofocusing; and gel filtration. In the examples of the present invention, the protein A chromatography step is followed by downstream cation exchange (SP-Sepharose) and anion exchange (Q-Sepharose) purification steps.

[0130] The proteins recovered in this way can be formulated into pharmaceutically acceptable carriers and used for various known diagnostic, therapeutic, or other applications of these molecules.

[0131] Pharmaceutical composition of bioreactor products

[0132] The product produced by the bioreactor of the present invention may be mixed with a pharmaceutically acceptable carrier (excipient) comprising a buffer to form a pharmaceutical composition for use in alleviating a disease or disorder. "Acceptable" means that the carrier must be compatible with the active ingredient of the composition (and preferably capable of stabilizing the active ingredient) and must not be harmful to the subject being treated. Examples of pharmaceutically acceptable excipients (carriers) comprising a buffer will be obvious to those skilled in the art and have been previously described. For example, see the literature [Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. KE Hoover]. In one example, the pharmaceutical composition described herein contains one or more anti-HLA-DQ8 antibodies that recognize different epitopes / residues of a target antigen.

[0133] The pharmaceutical composition of the present invention may comprise pharmaceutically acceptable carriers, excipients, or stabilizers in the form of lyophilized formulations or aqueous solutions (Remington: The Science and Practice of Pharmacy 20th Ed. (2000) Lippincott Williams and Wilkins, Ed. KE Hoover). Acceptable carriers, excipients, or stabilizers are non-toxic to the recipient at the dosage and concentration used and include buffers, e.g., phosphates, citrates, and other organic acids; antioxidants, including ascorbic acid and methionine; preservatives (e.g., octadecyldimethylbenzylammonium chloride; hexamethonium chloride; benzalkonium chloride, benzethonium chloride; phenol, butyl, or benzyl alcohol; alkyl parabens, e.g., methyl or propyl parabens; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; Proteins, e.g., serum albumin, gelatin, or immunoglobulin; hydrophilic polymers, e.g., polyvinylpyrrolidone; amino acids, e.g., glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextran; chelating agents, e.g., EDTA; sugars, e.g., sucrose, mannitol, trehalose, or sorbitol; salt-forming counterions, e.g., sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants, e.g., TWEEN™, PLURONICS™, or polyethylene glycol (PEG), may be included. Pharmaceutically acceptable excipients are further described herein.

[0134] In some examples, the pharmaceutical compositions described herein comprise liposomes containing bioreactor products, which can be prepared by any suitable method, e.g., methods described in the literature [Epstein, et al., Proc. Natl. Acad. Sci. USA 82:3688 (1985); Hwang et al., Proc. Natl. Acad. Sci. USA 77:4030 (1980); and U.S. Patents No. 4,485,045 and No. 4,544,545]. Liposomes with improved circulation times are described in U.S. Patent No. 5,013,556. Particularly useful liposomes can be generated by a reverse-phase evaporation method into a lipid composition comprising phosphatidylcholine, cholesterol, and PEG-derived phosphatidylethanolamine (PEG-PE). The liposomes are extruded through a filter of a limited pore size to obtain liposomes of a desired diameter.

[0135] The bioreactor product may be captured in microcapsules prepared by, for example, coacervation technology or interfacial polymerization, such as hydroxymethylcellulose or gelatin-microcapsules and poly-(methylmethacylate) microcapsules, respectively, in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles, and nanocapsules) or in macroemulsions. Exemplary techniques have been previously described, for example, see the literature [Remington, The Science and Practice of Pharmacy 20th Ed. Mack Publishing (2000)].

[0136] In other examples, the pharmaceutical compositions described herein may be formulated in a sustained-release format. Suitable examples of sustained-release formulations include a semipermeable matrix of a solid hydrophobic polymer containing an antibody, said matrix existing, for example, in the form of a molded article, for example, a film or a microcapsule. Examples of sustained-release matrices include polyesters, hydrogels (e.g., poly(2-hydroxyethyl-methacrylate) or poly(vinyl alcohol)), polylactide (U.S. Patent No. 3,773,919), copolymers of L-glutamic acid and 7-ethyl-L-glutamate, non-degradable ethylene-vinyl acetate, degradable lactic acid-glycolic acid copolymers, for example, LUPRON DEPOT™ (injectable microspheres composed of a lactic acid-glycolic acid copolymer and leuprolide acetate), sucrose acetate isobutyrate, and poly-D-(-)-3-hydroxybutyric acid.

[0137] Pharmaceutical compositions used for in vivo administration must be sterile. This is easily achieved, for example, by filtration through a sterile filter membrane. Therapeutic antibody compositions are typically placed in a container with a sterile access port, for example, in an intravenous solution bag or vial with a stopper that can be punctured with a subcutaneous injection needle.

[0138] The pharmaceutical compositions described herein may be in the form of a unit dose for oral, parenteral, or rectal administration or administration by inhalation or inhalation, e.g., tablets, pills, capsules, powders, granules, solutions or suspensions or suppositories.

[0139] To prepare a solid composition such as a tablet, the main active ingredient may be mixed with a pharmaceutical carrier, e.g., a conventional tableting ingredient, e.g., corn starch, lactose, sucrose, sorbitol, talc, stearic acid, magnesium stearate, dicalcium phosphate, or gum, and other pharmaceutical diluents, e.g., water, to form a solid pre-formulation composition containing a homogeneous mixture of the compound of this specification or a non-toxic, pharmaceutically acceptable salt thereof. When such a pre-formulation composition is described as homogeneous, it means that the active ingredient is evenly dispersed throughout the composition so that the composition can be easily subdivided into equally effective unit dosage forms such as tablets, pills, and capsules. Such a solid pre-formulation composition is then subdivided into unit dosage forms of the types described above containing 0.1 to about 500 mg of the active ingredient of the present invention. Tablets or pills of the novel composition may be coated or otherwise compounded to provide a dosage form that offers the benefit of an extended action. For example, tablets or pills may contain internal and external components, the latter being in the form of a coating covering the former. The two components may be separated by an enteric layer that resists disintegration in the stomach and allows the internal component to pass intact into the duodenum or delays release. Various materials may be used for this enteric layer or coating, and these materials include a number of polymeric acids and mixtures of polymeric acids and materials such as shellac, cetyl alcohol, and cellulose acetate.

[0140] Suitable surfactants include, in particular, nonionic formulations, e.g., polyoxyethylenesorbitan (e.g., Tween™ 20, 40, 60, 80, or 85) and other sorbitans (e.g., Span™ 20, 40, 60, 80, or 85). A composition containing a surfactant will conveniently contain 0.05 to 5% of the surfactant, which may be 0.1 to 2.5%. It will be understood that other components, e.g., mannitol or other pharmaceutically acceptable vehicles, may be added as needed.

[0141] Suitable emulsions may be prepared using commercially available lipid emulsions, e.g., Intralipid™, Liposyn™, Infonutrol™, Lipofundin™, and Lipiphysan™. The active ingredient may be soluble in a pre-mixed emulsion composition or otherwise soluble in an emulsion formed by mixing oil (e.g., soybean oil, safflower oil, cottonseed oil, sesame oil, corn oil, or almond oil) and phospholipids (e.g., egg phospholipids, soybean phospholipids, or soybean lecithin) with water. It will be understood that other ingredients, e.g., glycerol or glucose, may be added to adjust the tension of the emulsion. Suitable emulsions generally contain up to 20%, e.g., 5 to 20% oil.

[0142] The emulsion composition may be prepared by mixing a bioreactor product (e.g., antibody) with Intralipid™ or its components (soybean oil, egg phospholipid, glycerol, and water).

[0143] Pharmaceutical compositions for inhalation or aspiration include solutions, suspensions, and powders in pharmaceutically acceptable aqueous or organic solvents or mixtures thereof. Liquid or solid compositions may contain suitable pharmaceutically acceptable excipients as mentioned above. In some embodiments, compositions of the present invention are administered via oral or nasal breathing routes for local or systemic effects.

[0144] Preferably, the composition in a sterile, pharmaceutically acceptable solvent may be atomized using gas. The atomized solution may be inhaled directly from the atomizing device, or the atomizing device may be attached to a face mask, tent, or intermittent positive pressure breathing device. The solution, suspension, or powder composition may be administered, preferably orally or nasally, from a device that delivers the formulation in an appropriate manner.

[0145] Examples

[0146] Example 1. Silicon-based membrane for bubble-free gas delivery to high-density bioreactor cultures

[0147] Recent technological developments have enabled cell cultures to achieve very high cell densities, leading to high productivity of monoclonal antibodies.[1] However, controlling dissolved oxygen (DO) in these bioprocesses remains a challenging task, as it requires the delivery of high levels of oxygen and carbon dioxide to support high-density cultures. To achieve high delivery, methods such as microsparging, which releases micron-sized bubbles into the reactor, are used.[2] However, the use of microsparging increases the risk of bubble-induced cell death and foaming in the bioreactor, which can lead to premature run termination and product loss.[3,4] Furthermore, the addition of antifoaming agents and shear protectants to prevent foaming and bubble-induced cell death must be applied at levels that, in extreme cases, can be toxic to cells.[5]

[0148] To eliminate the challenges associated with bubble sparging, bubble-free aeration methods using porous and non-porous membranes have been investigated for cell culture applications. For example, polymer membranes with micron-sized pores have been described as bubble-free aeration methods, where the pressure balance between the culture and the gas allows bubble-free transfer to occur at the gas-liquid interface through the membrane pores.[6–8] Additionally, the use of hydrophobic membranes to prevent pore wetting issues has shown improved transfer compared to hydrophilic membranes, as the liquid trapped within the pores creates an additional barrier to gas transfer to the culture.[9] Non-porous silicone polymer-based membranes (e.g., polydimethylsiloxane, PDMS) have also been used for bubble-free gas exchange, where gas molecules diffuse through the dense polymer and are transferred to the culture at the membrane-culture contact surface.[10 to 12] Although porous and non-porous membranes have been applied to cell cultures, they have only been achieved at low densities (<20 e6 cells / mL) due to limitations in membrane design and challenges related to membrane operation.

[13] In particular, if gas and culture pressures are improperly balanced in porous membranes, micron-sized bubbles can form, leading to the risk of bubble-induced cell death and bioreactor foam formation. In non-porous membranes, the silicone-based tubing used is thick, which slows the transfer of gas molecules through the polymer and hinders sufficient gas exchange to support high-density cultures. To overcome the challenges associated with bubble sparging and support high-density cultures, alternative methods and materials for bubble-free gas exchange are required.

[0149] A new type of membrane has been developed that has properties capable of allowing enhanced gas transfer to support high-density cultures.

[14] The membrane contains small (ID 190 µm, OD 300 µm), thin-walled (55 µm) PDMS hollow fibers that are bundled and potted inside a unit that can be attached to a bioreactor via an external recirculation loop for gas transfer. Gas is sent through the hollow fiber lumen and the culture medium passes through the shell side of the membrane unit, and gas transfer occurs at the PDMS-liquid contact surface. Here, the use of such a membrane for gas transfer in high-density perfusion cultures (>20 e6 cell / mL) is described.

[0150] The study to measure kLa (mass transfer coefficient) was conducted in a 2-liter (L) bioreactor with a surface area of ​​2,500 cm² 2Similar oxygen (O2) mass transfer efficiencies were observed between the membrane and the microsparger. Enhanced mass transfer was achieved by increasing the recirculation flow rate, suggesting that optimization work can be performed to further elucidate the capabilities of the membrane. In addition to O2 transfer, air passing through the membrane lumen removed carbon dioxide (CO2) at a rate similar to perforated hole sparging, indicating the potential use of the membrane to eliminate all sparging in the bioreactor. To measure whether such a membrane provides sufficient DO to sustain high-density CHO cell cultures, several cell culture experiments were conducted. In the first experiment, a single membrane was attached to the bioreactor to replace microsparging for O2 addition (using perforated hole sparging for CO2 stripping). DO was maintained at 60% for several weeks and supported culture densities of 40e6 to 120e6 cells / mL. In subsequent experiments, a bubble-free bioreactor setup was tested, in which two membranes were arranged in series, one for CO2 stripping and the other for oxygenation. Cell densities of 20 to 30 e6 cells / mL were maintained for several weeks under sufficient oxygen delivery and culture at pCO2 of less than 120 mmHg. Using the above technique can improve high-density bioreactor cultures by eliminating the need to add shear protectants and antifoamers, which can have detrimental effects on the culture. Furthermore, if considered successful in replacing sparging, the membrane will be an innovative method enabling high cell density culture in both perfusion and fed-batch systems.

[0151] Method / Experiment

[0152] An initial test for gas exchange with a silicon membrane was performed in a 100L SUB.

[0153] Use a bioreactor bag (SUB) filled with 65L of water. 2.1m 2A PDMS membrane (PermSelect® silicon hollow fiber module) was attached to the recirculation loop of the SUB. 5 LPM water was recirculated through the side of the membrane shell. A DO probe was inserted into the SUB to monitor oxygen transfer. Before measuring O2 addition, O2 was removed from the reactor (%DO < 20%) by flowing N2 through the membrane lumen. Subsequently, O2 was flowed through the membrane at different rates (0.1 LPM, 1 LPM). For comparison, O2 at 0.1 LPM and 1 LPM was also flowed through a porous sparger (15 µm) in the SUB.

[0154] For kLa research, 2,500 cm 2A PDMS membrane (PermSelect® silicon hollow fiber module) was attached to the recirculation loop of a 2L glass bioreactor. 2L of phosphate-buffered saline (PBS) containing 1 g / L poloxamer 188 (pluronic) was heated to 37°C and recirculated through the shell side of the membrane using a centrifugal pump (Levitronix) at different flow rates (Table 1). A DO probe (Hamilton Visiferm) and a CO2 probe (Mettler Toledo) were attached to the bioreactor to monitor gas transfer. Before measuring O2 addition, N2 was flowed through the membrane to remove O2 from the reactor (%DO < 10%). For O2 addition, air was flowed through the membrane at different rates until saturation occurred (%DO level out of reach, ~100%). To compare membrane gas exchange with conventional sparging, air was also flowed through a perforated hole sparger and a microporous sparger (15 µm pores) at different flow rates. Prior to CO2 removal, 10% CO2 mixed with air was flowed through a membrane (pCO2 > 55 mmHg). For CO2 stripping, air was flowed through the membrane at varying velocities until CO2 stabilization was reached (pCO2 level deviation, ~1 to 2 mmHg). To compare with conventional CO2 removal methods, air was flowed through a perforated hole sparger at varying velocities to measure kLa. kLa was measured for the different conditions tested as follows:

[0155] In the absence of cells,

[0156]

[0157] since,

[0158]

[0159] Therefore, slope am.

[0160] Here, C *is the gas concentration at saturation (%DO or mmHg) (average of the last 10 measurement points at saturation), CO is the initial gas concentration, and C t is the gas concentration at time t.

[0161] Operation from normal state to abnormal state.

[0162] To measure whether silicon-based membranes can be used as a substitute for microsparging, 2,500 cm 2 A membrane (PermSelect® silicon hollow fiber module) was attached to the recirculation loop of a perfusion culture bioreactor after the hollow fiber (Fig. 1c). Dedicated CHO cell lines (CHO1) seeded at 10 e6 cells / mL were grown to 40 e6 cells / mL (3 days), and cell release began to maintain a density of 40 e6 cells / mL. The y-off for the membrane was kept closed during the ramp-up to density and for the first 4 days of steady-state operation, and %DO was maintained at 60% through microsparging and perforated hole sparging. After 4 days of steady-state operation, 50% of the recirculation (total 0.8 LPM, 0.4 LPM = 50%) was sent through the membrane. Additionally, the microsparger was turned off and the O2 gas line was switched to the membrane to provide 0 to 0.1 LPM oxygen, maintaining %DO at 60%. Finally, the perforated hole sparger (for CO2 stripping) was kept on, but the gas mixture was switched from 0.5 LPM O2 to 0.25 LPM O2 + 0.25 LPM air. To measure whether DO could be maintained during culture and the effect on the cells could be minimized, a membrane was used at 40 x 10⁻⁶ 6 They were cultured for 3 days at cells / mL under the above settings. After 3 days of steady-state operation, cell release was reduced and the cell density was set to 120 x 10⁶ 6We increased the cell / mL level to verify whether the membrane could support a high-density culture. Viability and LDH were monitored to measure culture vitality during operation. %DO (dissolved oxygen) was monitored to confirm that sufficient O2 was supplied to the cells through membrane gas exchange.

[0163] Ramp-up and operation at high cell density.

[0164] As a second test to measure the effect of the membrane on the culture during ramp-up to high cell density, 2,500 cm² 2 A membrane (PermSelect® silicon hollow fiber module) was attached to the recirculation loop of a perfusion culture bioreactor following the hollow fiber. Half of the total recirculation (total 0.8 LPM, 0.4 LPM = 50%) was delivered through the membrane on day 0 of culture. CHO1 was seeded at 10e6 and grown during an aberrant operation to measure the membrane's effect during density supported by the membrane and during ramp-up to maximum density. A mixture of 0.25 LPM air and 0.25 LPM O2 was delivered through a perforated hole sparger (for CO2 removal). To maintain %DO at 60% during culture, 0 to 0.1 LPM of O2 was delivered through the membrane to supply O2. Viability and LDH were monitored to measure culture vitality during operation. %DO was monitored to determine whether sufficient O2 was supplied to the cells via membrane gas exchange.

[0165] Bubble-free aeration in high-density perfusion culture

[0166] Based on kLa experiments regarding O2 addition, CO2 stripping, and microsparger replacement in high-density culture, a bubble-free setup (Fig. 1d) was tested to determine whether it could operate without sparging. Two 2,500 cm² 2Membranes (PermSelect® silicon hollow fiber modules) were attached to the recirculation loop of the perfusion culture reactor after the hollow fibers. The first membrane was used for CO2 stripping and pH control; a mixture of air, O2, and CO2 flowed to control pH during low-density culture and was subsequently switched to a mixture of air and O2 to strip CO2 during high-density culture. The second membrane was used for supplemental O2 addition to support DO at 60% during culture. Positive pressure was provided to the bioreactor by flowing 0.1 LPM air into the reactor headspace. Table 4 contains a list of the gas flows used daily during culture on each membrane. Dedicated CHO cell lines (CHO2) seeded at 1 e6 cell / mL were grown to 30 e6 cell / mL in a 2 L bioreactor and maintained at 25 e6 to 30 e6 cell / mL with cell release. During the density ramp-up, half of the recirculation flow (total 0.8 LPM, 0.4 LPM = 50%) was delivered across the membrane during the first 6 days. On day 7, as DO was not sustained by the 0.4 LPM recirculation flow, 100% of the recirculation (0.8 LPM) was sent across the membrane to strip CO2 and add O2. Viability and LDH were monitored to measure culture vitality during operation. %DO was monitored to determine whether sufficient O2 was supplied to the cells via membrane gas exchange.

[0167] Results and Discussion

[0168] O through gas exchange 2 Measurement of addition

[0169] First, to test gas transfer using a non-porous PDMS membrane, the transfer surface area is 2.1 m² 2A membrane was attached to the recirculation loop of a 100L sub-unit. The sub-unit was filled with 65L of water and recirculated through the membrane at 5LPM. Faster gas transfer across the membrane was observed compared to a built-in sparger (Fig. 10), which is attributed to the large surface area (2.1m²) of the fibers within the membrane unit. 2 This can be attributed to ). These results encouraged further investigation into the measurement of O2 addition and gas transfer coefficients (kLa) using membranes compared to conventional sparging methods.

[0170] Perforated hole and microporous sparging are commonly used in high-density cultures to provide sufficient DO, but bubble-ejection-related cell death and reactor foam formation can lead to premature run termination and product loss. To measure whether bubble-free membrane gas exchange is comparable to these sparging methods, a small 2L bioreactor was set up with a model fluid (PBS + 1 g / L Pluronic), and oxygen addition was monitored for different air flow rates and a constant recirculation rate (0.8 LPM) through flow path "B" (Fig. 3). Although kLa was highest in microsparging, membrane gas transfer achieved transfer coefficients on the same order of scale as microsparging. Perforated hole sparging was associated with the slowest O2 addition and the lowest kLa. However, while perforated hole sparging can be used for oxygen addition, its function is primarily for CO2 stripping, which is discussed in the next section.

[0171] [Table 1]

[0172]

[0173] An initial comparison of membrane gas transfer for sparging was performed using a single recirculation flow rate (0.8 LPM) and flow path. Different flow paths (Fig. 3) and recirculation rates were compared with the previously described 2L model bioreactor setup (2,500 cm²). 2Further research was conducted to determine whether membrane gas transfer could be improved to rival microsparging in the membrane. For flow path "A", no difference in kLa was observed with changes in recirculation rate. This may be because less transfer occurs as the liquid cannot flow into the densely packed high-density PDMS membrane fiber bundles located in the center of the unit (Table 2). In flow path "B", kLa increased with increasing flow rate, indicating that faster flow allows for faster gas exchange. Additionally, kLa comparable to microsparging was observed at high flow rates. Finally, higher kLa was achieved at lower flow rates in flow path "C" compared to flow path "B". These results indicate that most of the shell-side flow in "B" leaves the first outlet port, reducing the time the liquid is in contact with the fibers and potentially lowering gas transfer.

[0174] Although flow path "C" appears to be optimal for gas exchange across the membrane, recirculation flow was restricted in both paths "A" and "C". Membrane damage and rupture (Fig. 11) due to increased pump speed and pressure drop were observed for recirculation flow exceeding 0.5 LPM. To improve delivery using membranes, other membrane designs and flow paths that minimize pressure drop and the potential for membrane rupture must be investigated. Additionally, since high flow rates can induce shear in cultured cells, it is necessary to consider additional designs that reduce shear while providing high kLa.

[0175] [Table 2]

[0176]

[0177] CO by membrane gas exchange 2 Measurement of stripping

[0178] To operate a bioreactor by bubble-free gas exchange at high cell densities, CO2 removal through membranes is required. Here, CO2 stripping through membranes with air at different flow rates was compared to stripping using perforated hole sparging (Table 3). In a 2L model bioreactor system, 10% CO2 mixed with air was added to the bioreactor prior to stripping. Subsequently, CO2 was removed by sparging 100% air at different flow rates through either the membrane or a perforated hole sparger while maintaining a constant recirculation rate (0.4 LPM). Faster CO2 removal was observed via the membrane compared to perforated hole sparging. This can be attributed to the membrane's enhanced N2 transfer (~78% N2 in air) and its large surface area for transfer. These results are highly likely to be applied in the future for bubble-free bioreactor operation. As with O2 transfer, it is necessary to determine the optimal membrane design to increase the recirculation flow rate to improve gas transfer while maintaining low shear.

[0179] [Table 3]

[0180]

[0181] Replace the microsparger with a gas exchange.

[0182] Bubble sparging negatively impacts culture viability and may also increase the risk of foam formation and bioreactor loss. In particular, micron-sized bubbles formed by microporous spargers are considered a major cause of apoptosis, as the energy released during bubble ejection lyses surrounding cells. Furthermore, the foam generated by these bubbles is difficult to remove and often requires the addition of large amounts of antifoaming agents to the bioreactor during culture. Additionally, at high densities, more microsparging is required, leading to increased lysis and foam formation. Eliminating microsparging from cultures can help improve culture quality and extend bioreactor operation. This study describes an investigation into the use of silicon-based membranes instead of microsparging during steady-state bioreactor operation and during ramp-up to high cell densities.

[0183] Operation from normal state to abnormal state.

[0184] Initial tests were performed in steady-state cultures at high cell densities to assess the feasibility of replacing the microsparger with a silicon membrane for gas exchange. Dedicated CHO cell lines (CHO1) were cultured in a perfusion bioreactor at a density of 40 e6 cells / mL using perforated hole sparging (CO2 stripping + O2 addition) and microsparging (supplementary O2 addition) to maintain %DO at 60% (Figs. 4a and 5a to 5c). Once the density reached 40 e6, the culture was maintained at 60% DO with standard sparging for 4 days to establish a baseline %DO profile (Fig. 5a). After 4 days, half of the 0.8 LPM culture recirculation flow (0.4 LPM) was returned through the membrane, O2 from the microsparger was attached to the membrane gas exchanger, and a mixture of 0.25 LPM air and 0.25 LPM O2 was sent through the perforated hole sparger (Fig. 5b). DO was maintained at 60% by controlling the increase or decrease (0 to 0.1 LPM) of O2 flow through the membrane. During membrane initiation, unlike microbubbles, DO fluctuated due to changes in reaction time using the membrane; therefore, the gain was reduced and the integration was increased to improve control over fluctuations (Fig. 5b). After operating the membrane in a steady state for 3 days, density was increased by reducing cell release, and it was measured whether the membrane could maintain DO at higher densities. A density of 120 e6 was achieved, but there were fluctuations in DO during ramp-up to higher densities (Figs. 4a and 4c). It was hypothesized that water, which may pass through these membranes, could block the fibers and filters at the gas outlet during operation and reduce gas delivery until higher gas flow displaces the water from the fibers. Further research is needed to determine whether this delivery duration is reduced during operation due to water blockage in the gas flow pathway, or whether the membrane cannot be controlled during abnormal operation.In addition to maintaining %DO during operation, there was no apparent effect of the membrane on culture vitality, with viability and lactate dehydrogenase (LDH) comparable to the control group (Figs. 4b and 4c). LDH increased when cell density increased, which is believed to be primarily due to the presence of higher cell density rather than the effect of the membrane on the culture. These results support the potential for applying membranes to replace microsparging in high-density cultures. Further studies will be conducted to understand the effect of the membrane during ramp-up to high density, thereby providing a better understanding of the membrane's impact on culture.

[0185] Ramp-up and operation at high cell density.

[0186] To determine whether a membrane could be used to control DO during ramp-up to high cell density, the membrane was placed downstream of the hollow fiber in the culture recirculation loop. Additionally, to prevent the fiber and gas outlet filter from becoming clogged with water during operation, a sterile discharge bottle was attached to the gas outlet of the membrane unit. Before inoculating cells, half of the 0.8 LPM recirculation flow (0.4 LPM) was delivered through the membrane. Cells were inoculated at 10 e6 cells / mL and cultured at high density without cell release. Viability using the membrane was similar to that of the control reactor with conventional sparging (Fig. 6b). However, density reached only ~100 e6 cells / mL compared to ~130 e6 cells / mL with conventional sparging, indicating that the membrane may have a slight effect on cells during density ramp-up (Fig. 6a). While higher cell density is associated with higher LDH, the LDH in the bioreactor was similar, which may indicate some negative impact of the membrane on culture viability during operation (Fig. 6c). Current membrane designs containing densely packed fibers are hypothesized to cause shear or damage to the cell membrane, thereby slowing growth. If an alternative membrane design with improved flow pathways and more spaced fibers is implemented, shear and cell damage during membrane operation can be reduced, and higher density can be achieved.

[0187] During culture, DO was controlled to 60% via perforation sparging and membrane gas exchange. Initially, 0.25 LPM air passing through the perforation sparger was replaced with 0.5 LPM O2. When the O2 through the perforation sparger reached its maximum (0.5 LPM), additional O2 was supplied through the membrane as needed, ranging from 0 to 0.1 LPM O2. After DO control was adjusted to allow additional O2 to be added via membrane exchange, DO fluctuated around the 60% setpoint (Fig. 7). These fluctuations were not reduced by changing the PID control loop gain and integral, indicating that the membrane was initially oversized for low densities. As density increased, O2 demand increased, and the fluctuations stabilized on day 5 (Fig. 7a). Alternative control parameters can be implemented to reduce these fluctuations at low densities. It is important to note that Mass Flow Controller (MFC) function shutdowns occurred during the run, affecting the DO profile and control. In particular, from days 2 to 4, oxygen through the perforated sparger was periodically interrupted, and the membrane became the sole source of O2. On day 3, O2 supply through the perforated sparger was interrupted, and since DO dropped to 0%, the gas supply was temporarily switched to another MFC (passive DO control) to repair the initial MFC (Fig. 7a, red). The control group was returned to the original MFC on days 4 to 5, but some additional fluctuations occurred during the run as the MFC was briefly interrupted during operation (Fig. 7b, red). As previously discussed, further research is needed to evaluate whether the loss of DO control due to shear from the membrane or a malfunctioning MFC can negatively affect culture viability and whether density decreased compared to the control group. Further testing is required to measure whether the exhaust bottle at the membrane gas outlet helps prevent DO fluctuations by allowing water to flow out from the fibers, while simultaneously preventing filter wetting.Despite the challenges caused by the cessation of MFC function, O2 flow through the membrane did not reach a maximum flow (0.1 LPM) and was sufficient to maintain a very high cell density (up to ~100 e6 cells / mL), which guarantees the feasibility of membrane application to replace microsparging in high-density cultures.

[0188] Bubble-free bioreactor operation

[0189] The elimination of sparging from the bioreactor can improve high-density cultures, and the elimination of bubbles reduces bubble-ejection-related cell death and eliminates the need for the addition of antifoamers. Here, two membranes were placed downstream of the hollow fibers (e.g., the "TFF (Tangential Flow Filtration) module" of Fig. 1d in the recirculation loop of the perforation bioreactor (e.g., illustrated in Fig. 1d)). The first membrane was used to replace the perforated hole sparger for CO2 stripping and slight oxygen addition, where a mixture of oxygen and air was sent through the lumen of the membrane unit. Additionally, the first membrane controls the pH by supplying CO2 during low-density operation at the beginning of the culture. The second membrane was used solely for oxygen addition to replace the microsparger, as previously demonstrated. To challenge the membrane for bubble-free bioreactor operation, a second dedicated CHO cell line (CHO2) with higher shear sensitivity and higher oxygen requirements was used. When applying cell release to maintain a normal operating state of 25e6 to 30e6 cells / mL, cells were inoculated at 1e6 cells / mL and cultured at a density of 30e6 cells / mL. The reactor was operated for 17 days without bubbles without adding antifoaming agents during operation. In addition, DO remained close to 60% throughout the entire operating period and did not reach 0%, indicating that the membrane provided sufficient O2 to sustain culture.

[0190] The ramp-up to density in the bubble-free reactor was 1 day slower than in the control reactor (ATF with perforated hole sparging + microsparging), and LDH was higher, indicating that shear from the membrane can affect culture vitality (Fig. 8). DO was generally maintained at 60%, but the control was not optimal and fluctuations occurred under different conditions during operation (Fig. 9). The O2 requirements of the CHO2 cell line were significantly higher than those of CHO1, and a large flow of O2 had to be added during operation to sustain DO (Table 4). In particular, O2 requirements continuously increased despite steady-state operation, requiring the application of higher O2 flows throughout the operation. Consequently, fluctuations in DO occurred while adjusting the MFC and oxygen flow. Additionally, half of the recirculation flow (0.4 LPM) was delivered across the membrane at the start. However, to support the high oxygen requirements, the entire recirculation flow (0.8 LPM) was delivered across the membrane on day 7. Finally, it is important to note that air is required to strip CO2. Although air was cut off between 5 and 6 days to supply sufficient O2 at once during culture, CO2 increased in response. There is a hypothesis that the presence of N2 in the air increases efficiency during stripping, and thus air or N2 becomes required for CO2 removal during bubble-free operation. In future bubble-free runs, an MFC allowing for higher oxygen flow will be investigated for the optimization of membrane unit operation.

[0191] [Table 4]

[0192]

[0193] conclusion

[0194] A bubble-free gas delivery method using a silicon-based membrane unit comprising packed bundles of thin-walled hollow fibers was disclosed. O2 delivery through this membrane was sufficient to sustain 60% DO at high cell densities (100 to 120 e6 cells / mL) without significantly affecting culture viability during operation. Bubble-free gas delivery was achieved using two membrane devices: a first device for CO2 stripping and a second device for O2 addition. Cells were able to survive for several weeks in cultures at high cell densities (25 to 30 e6 cells / mL), and DO was maintained at nearly 60% during bubble-free culture. Furthermore, antifoaming agents were not required in bubble-free culture, which often adhere to the vessel walls and hollow fibers to form layers during culture. In future studies, DO control will be optimized to reduce and prevent fluctuations during operation. Additionally, further investigation into the shear effects of this membrane is required, and additional designs to reduce shear will be identified. This study is a preliminary investigation into the use of silicon-based membranes for gas delivery in high-density cell cultures (>20 e6 cells / mL) and has potential for application in both fed-batch and perfusion processes. The implementation of these membranes alleviates many of the problems associated with conventional sparging, thereby reducing the likelihood of premature run termination during high-density operation.

[0195] References

[0196] The following references are cited in this application. The full text of each of these is incorporated herein by reference.

[0197] 1. Kunert, R. and D. Reinhart, Advances in recombinant antibody manufacturing. Appl Microbiol Biotechnol, 2016. 100 (8): p. 3451-61.

[0198] 2. Qi, H., et al., The art & science of micro-sparging in high-density perfusion cultures of animal cells, in Animal Cell Technology: From Target to Market. 2001, Springer. p. 412-415.

[0199] 3. Liu, Y., et al., Effects of bubble-liquid two-phase turbulent hydrodynamics on cell damage in sparged bioreactor. Biotechnol Prog, 2014. 30 (1): p. 48-58.

[0200] 4. Godoy-Silva, R., C. Berdugo, and J.J. Chalmers, Aeration, Mixing, and Hydrodynamics, Animal Cell Biroeactors, in Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology, M.C. Flickinger, Editor. 2010, John Wiley & Sons, Inc.

[0201] 5. Velugula-Yellela, S.R., et al., Impact of media and antifoam selection on monoclonal antibody production and quality using a high throughput micro-bioreactor system. Biotechnol Prog, 2018. 34 (1): p. 262-270.

[0202] 6. Wagner, R. and J. Lehmann, The growth and productivity of recombinant animal cells in a bubble-free aeration system. Tibtech, 1988. 6 .

[0203] 7. Buntemeyer, H., B.G.D. Bodeker, and J. Lehmann, Membrane-stirrer-reactor for bubble free aeration and perfusion. 1987: p. 411-419.

[0204] 8. Lehmann, J., J. Vorlop, and H. Buntemeyer, Bubble-free Reactors and Their Development for Continuous Culture with Cell Recycle. Animal Cell Biotechnology, 1988. 3 : p. 221-237.

[0205] 9. Balgobin, R. and D. Karamanev, Bubble-free oxygen and carbon dioxide mass transfer in bioreactors using microporous membranes. 2012.

[0206] 10. Velez-Suberbie, M.L., et al., Impact of aeration strategy on CHO cell performance during antibody production. Biotechnol Prog, 2013. 29 (1): p. 116-26.

[0207] 11. Emery, A.N., D.C.H. Jan, and M. Al-Rubeai, Oxygenation of intensive cell-culture system. Appl Microbiol Biotechnol, 1995. 43 : p. 1028-1033.

[0208] 12. Qi, HN, et al., Experimental And Theoretical Analysis of Tubular Membrane Aeration for Mammalian Cell Bioreactors. Biotechnol Prog, 2003. 19 : p. 1183-1189.

[0209] 13. Zhang, S., A. Handa-Corrigan, and R. E. Spier, A Comparison of Oxygenation Methods for High-Density Perfusion Cultures of Animal Cells. Biotechnology and Bioengineering, 1993. 41 : p. 685-692.

[0210] 14. Orgill, JJ, et al., A comparison of mass transfer coefficients between trickle-bed, hollow fiber membrane and stirred tank reactors. Bioresour Technol, 2013. 133 : p. 340-6.

[0211] 기타 양태

[0212] All characteristic configurations disclosed herein may be combined in any combination. Each characteristic configuration disclosed herein may be replaced by other characteristic configurations that provide the same, equivalent, or similar purpose. Accordingly, unless otherwise expressly stated, each disclosed characteristic configuration is merely an example of a general series of equivalent or similar characteristic configurations.

[0213] From the foregoing description, those skilled in the art can easily identify the essential features of the present invention and adapt it to various uses and conditions by making various changes and modifications to the present disclosure without departing from the spirit and scope thereof. Accordingly, other embodiments are also within the scope of the claims.

Claims

Claim 1 A method for culturing Chinese Hamster Ovary (CHO) cells in a bioreactor, comprising the step of providing mass transfer of gas to / from the bioreactor without generating bubbles inside the bioreactor, wherein the mass transfer of gas to / from the bioreactor is provided by two or more gas transfer modules, and wherein the gas transfer module comprises a non-porous, gas-permeable membrane comprising a plurality of hollow fibers, wherein the bioreactor is a perfusion bioreactor, and the cell density of the bioreactor is at least 20 x 10 6 A method comprising cell / ml, wherein the two or more gas delivery modules each comprise a first flow path through the hollow fibers for passing one or more gases and a second flow path around the hollow fibers for flowing cell culture medium and / or cells, wherein at least one gas delivery module comprises an oxygen flow path through the hollow fibers and at least one gas delivery module comprises an air / carbon dioxide flow path through the hollow fibers, and the non-porous, gas-permeable membrane comprises silicone or polydimethylsiloxane (PDMS). Claim 2 delete Claim 3 delete Claim 4 delete Claim 5 delete Claim 6 A method according to claim 1, wherein the gas transfer module is located outside the bioreactor. Claim 7 A method according to claim 1, wherein the plurality of hollow fibers provide a flow path through which the culture medium and cells travel through spaces separating the hollow fibers. Claim 8 In paragraph 7, the method in which the spaces are homogeneous or heterogeneous. Claim 9 A method according to claim 7, wherein the spaces are of a size sufficient to pass through the cell without causing shear force on the cell. Claim 10 In claim 7, the method wherein the spaces include a distance of 15 to 2,000 μm. Claim 11 A method according to claim 10, wherein the spaces comprise distances of 15 to 30 µm, 20 to 40 µm, 30 to 60 µm, 40 to 80 µm, 60 to 120 µm, 80 to 160 µm, 100 to 200 µm, 150 to 300 µm, 200 to 400 µm, 200 to 500 µm, 200 to 600 µm, 200 to 700 µm, 200 to 800 µm, 200 to 900 µm, 200 to 1,000 µm, 500 to 2,000 µm, or a combination of these distances. Claim 12 In claim 6, the method wherein the flow of the cell culture medium and / or cells comprises tangential flow, axial flow, or a combination thereof. Claim 13 A method according to claim 6, wherein the flow of the cell culture medium and / or cells is at a rate sufficient to maintain culture homogeneity without causing shear force to the cells. Claim 14 delete Claim 15 In claim 1, the cell density of the bioreactor is 20x10 6 cell / ml, 30x10 6 cell / ml, 40x10 6 cell / ml, 50x10 6 cell / ml, 60x10 6 cell / ml, 70x10 6 cell / ml, 80x10 6 cell / ml, 90x10 6 cell / ml, 100x10 6 cell / ml, 110x10 6 cell / ml, 120x10 6 cell / ml, 130x10 6 cell / ml, 140x10 6 cell / ml, 150x10 6 cell / ml, 160x10 6 cell / ml, 170x10 6 cell / ml or 180x10 6 cell / ml method. Claim 16 A method according to claim 1, wherein the above method prevents the formation of foam. Claim 17 A method according to claim 1, wherein the bioreactor does not include headspace. Claim 18 A method according to claim 1, wherein the method does not require an antifoaming agent during cell culture. Claim 19 delete Claim 20 A bioreactor system for high-density cell culture comprises a bioreactor vessel for growing Chinese Hamster Ovary (CHO) cells in a cell culture medium and a liquid flow path that fluidly communicates with said bioreactor vessel, wherein the liquid flow path forms a circuit for translocating the cell culture medium through a first membrane gas transfer module and a second membrane gas transfer module outside said bioreactor vessel, said first and second membrane gas transfer modules comprise a non-porous, gas-permeable membrane comprising a plurality of hollow fibers, said bioreactor is a perfusion bioreactor, and said cell density of said high-density cell culture is at least 20x10 6 A bioreactor system comprising cell / ml, wherein the first and second membrane gas transfer modules each comprise a first flow path through the hollow fibers for passing one or more gases and a second flow path around the hollow fibers for flowing cell culture medium and / or cells, at least one gas transfer module comprises an oxygen flow path through the hollow fibers, at least one gas transfer module comprises an air / carbon dioxide flow path through the hollow fibers, and the non-porous, gas-permeable membrane comprises silicone or polydimethylsiloxane (PDMS). Claim 21 In claim 20, the above-mentioned first membrane gas transfer module is a bioreactor system for adding oxygen to the cell culture medium. Claim 22 In claim 20, the second membrane gas transfer module is for stripping carbon dioxide from the cell culture medium, in a bioreactor system. Claim 23 A bioreactor system according to claim 21, wherein the first membrane gas transfer module comprises an oxygen flow path and a cell culture medium flow path, and the oxygen flow path and the cell culture flow path are separated by a gas-permeable membrane. Claim 24 A bioreactor system according to claim 22, wherein the first membrane gas transfer module comprises an air / carbon dioxide flow path and a cell culture medium flow path, and the air / carbon dioxide flow path and the cell culture flow path are separated by a gas-permeable membrane. Claim 25 A bioreactor system according to claim 20, wherein the liquid flow path forming the circuit further comprises one or more additional elements. Claim 26 A bioreactor system according to claim 25, wherein one or more of the above additional elements are cell harvesting filters. Claim 27 A bioreactor system according to paragraph 25, wherein one or more of the above additional elements are perfusion pumps. Claim 28 A bioreactor system comprising an additional oxygen source in paragraph 20. Claim 29 A bioreactor system according to paragraph 20, further comprising a source of an air / carbon dioxide mixture. Claim 30 A bioreactor system according to claim 21, further comprising an oxygen sensor for controlling the level of oxygen introduced into the cell culture medium through the first membrane gas transfer module. Claim 31 A bioreactor system according to claim 22, further comprising a pH sensor for controlling the level of carbon dioxide introduced into the cell culture medium through the second membrane gas transfer module. Claim 32 In paragraph 20, the cell density of the high-density cell culture is 20x10 6 cell / ml, 30x10 6 cell / ml, 40x10 6 cell / ml, 50x10 6 cell / ml, 60x10 6 cell / ml, 70x10 6 cell / ml, 80x10 6 cell / ml, 90x10 6 cell / ml, 100x10 6 cell / ml, 110x10 6 cell / ml, 120x10 6 cell / ml, 130x10 6 cell / ml, 140x10 6 cell / ml, 150x10 6 cell / ml, 160x10 6 cell / ml, 170x10 6 cell / ml or 180x10 6 A bioreactor system with a cell / ml capacity. Claim 33 A bioreactor system according to claim 20, wherein the first membrane gas transfer module and the second membrane gas transfer module add / add or remove gases to / from the cell culture medium without forming bubbles. Claim 34 delete Claim 35 delete Claim 36 delete Claim 37 delete Claim 38 delete

Citation Information

Patent Citations

  • Bubble-free air supply and solid-liquid separation integrated membrane biomembrane reactor taking indissoluble gases as fermentation raw materials

    CN101831382A

  • Methane oxidation methods and compositions

    WO2017066725A1

  • Method and apparatus for cultivation of suspensible animal cell

    JP1983116678A

  • Devices and methods for producing and using high density cells and products therefrom

    JP2003521877A